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STRUCTURE AND FUNCTION STUDIES OF SELENIUM SUBSTITUTED NUCLEIC ACIDS
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WEN ZHANG

Under the Direction of Dr. Zhen Huang

ABSTRACT
Nucleic acids are responsible for the storage of genetic information and directly participate in
gene replication, transcription and expression, and thereby the control of nucleic acids leads to the
regulation of genetic information flow and gene expression. Meanwhile, many non-coding RNAs are involved in signal transduction directly. Moreover, nucleic acid-based therapeutic strategies have been
lead to drug candidates and are effective tools in drug discovery and disease study at the molecular level
as well as the genetic level. Consequently, the 3D crystal structure study and related functional research
on natural and unnatural nucleic acids have become very popular area, expanding their potential application in medicinal and biological chemistry.
Since oxygen, sulfur, selenium and tellurium are in the same elemental family (VIA) in the periodic table, we anticipate that oxygen atoms in nucleic acids can most likely be replaced with the other
chalcogen atoms without causing significant perturbations. Owing to the special K edge and unique
properties of selenium, our lab has completed the chemical and enzymatic synthesis of unnatural nucle-

ic acids with selenium substitutions at various positions. The selenium functionality in nucleic acid is essential for nucleic acids’ structural determination at the atomic level. Additionally this novel elemental
feature (atomic size and electronic nature) provides nucleic acids with unique properties. In addition,
the selenium derivatization can facilitate crystal growth. Other chalcogen elements are applicable as
well to modify nucleic acid, generating some special biofunctions, like the application of
phosphorthioate oligonucleotide in gene therapy. This dissertation will outline the chalcogen elements
(especially selenium) modifications of nucleic acids, including syntheses strategies, structure studies and
potential therapeutic applications. Our research work here tries to show that (1) Selenium functionality
is able to facilitate the crystal structure determination, by both helping solve phase problem and accelerating crystal growth; (2) Selenium functionality can generate special capability to nucleic acids, like
improved base pair fidelity, novel atomic interactions and feasibility to be biological chemistry probe; (3)
Selenium derivatized oligonucleotides are extraordinary good candidates for gene therapy discovery,
considering its stability under nuclease environment. In general, these atom-specific replacements generate a new paradigm of nucleic acids.
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1.

INTRODUCTION
1.1 Nucleic Acids—Important Molecules for Biofunction Studies and Drug Discovery
Nucleic acids are the storage of genetic information and directly participate in gene replication,

transcription and expression, and the control of nucleic acids can lead to modulation and regulation of
genetic information flow and gene expression1,2. In addition, many non-coding RNAs, like ribosomal
RNA, riboswitch and microRNA, are participated in signal transduction directly by regulatory functions3,4.
Moreover, nucleic acid-based therapeutic strategies, where the natural gene, instead of protein, is recognized as drug targets and the modified oligonucleotides (DNAs and RNAs) are applied as drug candidates, are effective tools in drug discovery and disease study at the molecular level as well as the genetic level5,6. Therefore, nucleic acids related research is essential for better understanding diseases and
identifying novel drug candidate and target for development of therapeutics with high efficiency to treat
some world-wide diseases. Because of the advantages of low toxicity, notable efficacy and high specificity, numerous nucleic acid-based potential therapeutics are under development or in clinical trials, including antisense oligonucleotides, siRNAs, miRNAs, ribozymes and DNazymes and nucleic acid
aptamers7-9. Instead of the traditional attacking of aberrant proteins, modulating expression of specific
diseases’ gene by these nucleic acids therapies can lead to better treatment. Research activities in this
area require further development of new nucleic acid analogs with improved properties.
On the other hand, the unique structures of DNA and RNA provide nucleic acids multiple functions and properties. The negative charges on phosphate groups make nucleic acids soluble in water,
and the hydrophobic nucleobases in the center can form Watson-Crick hydrogen bonds. Additionally,
the complicated RNA secondary and tertarial structures generate enzyme-like catalytic functions. Recently, X-ray crystallography has been the most powerful technical tool to provide researchers detailed
3-D structural information of nucleic acids at atomic level, which is helpful for us to discover new drug
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candidate and understand nucleic acids related biological processes mechanism, such as DNA replication, ribozyme catalysis, DNA transcription and RNA translation10,11. Despite the bottle-necks of nucleic
acid crystallography and phase problem, it is greatly promising for researchers to rely on it for nucleic
acid function study and gene therapy development12,13.

3
1.2 Synthesis of Selenium Derivatized Nucleic Acids (SeNA)
Since oxygen atom is one of essential elements in nucleic acids, it is anticipated that the atomspecific substitution of oxygen atoms with the other chalcogen atoms is a potential useful chemical
strategy to generate tremendous improvements of nucleic acids without causing significant alterations
in native structures, functions and protein interaction (such as higher bioavailability and stability). Sulfur
(S), selenium (Se) and tellurium (Te) are the elements following oxygen in the VIA group of the periodic
table. Selenium element was discovered in 19th century, and little systematic research was conducted at
that time owing to the toxicity. With the modern chemical and biological technologies, the existence of
selenium in natural organisms was demonstrated14. Nowadays selenium is considered as an essential
element, i.e. the trace micronutrient that functions as cofactor for reduction of antioxidant enzymes15.
Two Se-containing special amino acids, selenomethionine and selenocysteine, have been found in nature16,17, and several studies have suggested there is a possible link between selenium deficiency and
many types of diseases, like cancer, HIV/AIDS and diabetes. Overall, its functions in biomolecules have
attracted increasing attention of scientific communities. Like sulfur, selenium was also found to exist in
natural tRNA in the form of 2-selenouridine and 5-[(methylamino)methyl]-2-selenouridine (mnm5se2u)
with the corresponding natural 2-thiouridine as a precursor14. The reaction was catalyzed by 2selenouridine synthase with the selenophosphate as the selenium donor, and the S atom at 2-position
was replaced by Se18,19. This selenium functionality is usually found at the anticodon wobble positions of
several bacterial tRNAs, and interestingly may provide the translation process with higher accuracy and
efficiency20. However, compared with Se-derivatized proteins, research on selenium functionalized nucleic acids is relatively limited owing to the stability, availability and other challenges. This fact stimulates our lab to study the novel synthesis and property of selenium modified unnatural nucleic acids.
Because of its larger atomic size (atomic radius, O: 0.73 Å, S: 1.02 Å, Se: 1.16 Å) and its higher electron
density, selenium can be used to derivatize nucleic acids (Figure 1.1), thereby generating potential nu-
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cleic acids with many unique and novel properties. As they are in the same elemental group, oxygen and
selenium and have closely-related chemical and electronic properties. This allows almost complete retention of the native structures, functions, and protein recognitions after the nucleic acid modification
by replacing oxygen atoms with selenium. This atom-specific replacement allows many modification
choices in introducing the selenium elements, because of the multiple oxygen atoms in nucleic acids. By
screening for the ideal substitution sites, the multiple choices allow minimization of the potential perturbations. Furthermore, because of their larger atomic sizes, compared to oxygen (1.16 Å vs 0.73 Å),
and their higher electron densities, Se- derivatized nucleic acids may possess many unique properties.

Se
O
N

NH

O

5'

P O

O

N
O

-

O
3'

O

(Or other nucleobases)

N

NH2

OH or (H)

Figure 1.1 Se-derivatized nucleic acids (SeNA).

Recently the synthesis, structure and function studies of selenium-derivatized nucleic acids
(SeNA) have been successfully pioneered by Huang and co-workers21-23. The Se-functionalities at various
positions, including the sugar 2’, 4’ and 5’ positions, nucleobases, and phosphate groups, have been accomplished by Huang’s and other research groups. SeNA provides extra research advantages in chemistry and biology areas, like chemical biology, molecular biology, and structural biology, i.e. X-ray crystallography. This atomic Se-substitution also provides novel insights into structure and function of nucleic
acids, including base pair recognition, duplex stability and fidelity, catalysis, and non-coding RNA function24-26.
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In the sugar modification with selenium, the 5’-MeSe-derivatized phosphoramidites, including A,
C, G, T and U, were first synthesized by Huang’s group27. This route was achieved by activation of the 5’position by good leaving groups, like Ts, Ms or Br, followed by an SN2 substitution with the selenide reagents in presence of phase transfer catalyst. Experiments showed that these 5’-Se-modified
phosphoramidites are stable and can be incorporated into oligonucleotides with high yields. It was also
interestingly found by other researchers that the nucleic acid dimer with selenium functionality at 5’
bridging position possessed some toxicity28, which was worthy for biological application and drug discovery. (Figure 1.2)

T

RO
O

B

HSe
O

OH OH (or H)

O
O
R P

T

Se
O
OH

Figure 1.2 5’-selenium modified nucleoside and TT dimer. (B=nucleobase)

After the demonstration of the Se-functionality stability, a novel phosphoramidite compound
(2’-α-methylseleno uridine phosphoramidite) was first synthesized by Huang’ laboratory, with the 3’,5’protected-2,2’-anhydrous uridine as the intermediate29. It showed fine stability in solid-phase synthesis
and offered a high coupling efficiency (99% yield). In this work, the structure of a selenium-functionality
containing DNA decamer 5’-GCGTAU2’-SeMeACGC-3’ was determined at high resolution (1.3 Å), and the
structure was successfully solved based on the selenium anomalous signal. Later, the strategy to introduce 2’-selenium functionality was improved to get higher yield30. In the experiment both U and C nucleoside containing 2’-selenium modification were synthesized. The synthetic strategy was shown in
Scheme 1.1. Also a novel self-complementary 8mer A-form DNA 5’-GU2’-SeMeGTACAC-3’ was crystallized

6

Scheme 1.1 Synthesis of 2’-methylseleno containing uridine and cystidine phosphoramidite and DNAs.
(a) (Ph)2CO3, Na2CO3, DMF; (b) DMTr-Cl, Py; (c) NaSeCH3, EtOH-THF; (d) 2- cyanoethyl N,N-diisopropylchlorophosphoramidite and N,N-diisopropylethylamine in CH2Cl2; (e) synthesis of oligonucleotides on
solid phase; (f) Ms-Cl, TEA, THF; (g) toluene/ tetrahexylammonium hydrogen sulfate, Na2CO3 (satd); (h)
(Bu)4N+ F-, THF; (i) TMS-Im, then Ac2O, TEA and DMAP in THF; (j) TMS-Im, then POCl3-triazole-TEA in
CH3CN; (k) NH4OH.
easily and the structure was determined using selenium to solve phase problem. In different to the 2’Se-modified pyrimidine compound synthesis, the same strategy was not working for purine nucleoside
synthesis. This fact forced scientists to pioneer novel chemical approach to introduce selenium functionality into 2’-position. In Micura’s group, trifluoromethanesulfonyl (Tf) group was applied as good leaving
group at 2’-β-position of RNA A nucleoside, followed by the replacement of selenium element in a SN2
reaction31. Later guanosine RNA nucleoside with selenium at 2’-position was synthesized as well using
similar strategy. It should be noted that DTT is necessary in the 2’-selenium-modified purine synthesis,
due to the instability of selenium functionality under oxidation condition. Recently in Huang’s lab the
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Scheme 1.2 Synthesis of the 2’-selenomethyl-2’-deoxyguanosine phosphoramidite.

DNA purine nucleoside analogues with 2’-selenium-derivatization were synthesized by a novel
strategy32,33. In the synthesis, no DTT reducing reagent was needed, and 2’-position was also activated
by Tf group. By this novel and convenient strategy, modified DNA nucleosides were synthesized and incorporated into oligonucleotides for structural studies. The synthesis of 2’-Se-G was shown in scheme
1.2.
4’-Thio-modification has attracted a lot of interest because of some special properties, such as
anti-virus stability. Similarly, the replacement of the sugar ring oxygen with the selenium generates the
4’-seleno nucleoside. The syntheses of the 4’-selenocytidine and 4’-selenouridine were first achieved by
Matsuda’s group using stereoselective seleno-Pummerer reaction34. Later, a modified strategy was applied by Jeong’s group to achieve 4’-seleno nucleoside synthesis, and the crystal structure of the 4’-Senucleosides was also determined35. Their results indicated that the replacement of oxygen at 4’-position
by selenium will cause the southern conformation. Later, Pinto’s laboratory applied the Pummerer rear-
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rangement to synthesize both pyrimidine and purine nucleosides containing the 4’-seleno functionality36. Basically all the four types of 4’-selenium-modified nucleosides can be accomplished now.
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5'-Oligonucleotide P O
O

O

N

DMTr O

O

O
P

N P
Oligonucleotide 3'

O

O

O

O
O

f

OCH2CH2CN

Scheme 1.3 Synthesis of the 4-Se-thymidine phosphoramidite and Se-DNAs. a) TMS-Im and MeCN. b)
1H-Triazole, POCl3, Et3N. c) (NCCH2CH2Se)2, NaBH4, EtOH. d) 10% Et3N in MeOH. e) 2-Cyanoethyl N,N
diisopropyl (chloro) phosphoramidite and EtN(i-Pr)2 in CH2Cl2. f) Solid-phase synthesis.
The Se-nucleobase modifications of nucleic acids were first accomplished by Huang’s laboratory
recently22,23. The Se-functionality was introduced to the 4-position of thymidine (Scheme 1.3) by selective activation of the 4-position with triazoyl group, followed by the introduction of 2-cyanoethyl
selenide using the Huang’s reagent [(CNCH2CH2Se-)2] to protect selenium functionality24. The corresponding 4-Se-T phosphoramidite was successfully synthesized and then incorporated into oligonucleotides in a high yield. In this substitution reaction the selenium atom was introduced into nucleobase in
high yield, and it encouraged us to explore more substitution methods. Later, the 6-Se-deoxyguanosine
phosphoramidite was also synthesized for the first time37. The 6-position of guanosine was activated by
2,4,6-triisopropylbenzene-1-sulfonyl group, followed by the introduction of the Se- functionality. This
novel 6-Se-G-phosphoramidite was successfully incorporated into oligonucleotides by solid-phase synthesis in high yield.

9

Scheme 1.4 Synthesis of the 6-(2-cyanoethyl)seleno deoxyguanosine phosphoramidite (3) and oligonucleotides (4). a) TIBS, DMAP, TEA, CH2Cl2, room temperature; b) diselenide, NaBH4/EtOH, -5 °C, 80% yield
in two steps; c) phosphoramidite, BTT, CH 2Cl2, 75% yield; d) solidphase synthesis. TIBS=2,4,6triisopropylbenzene-1-sulfonyl chloride, DMAP=4-dimethylaminopyridine, diselenide = (NCCH2CH2Se)2,
phosphoramidite=2-cyanoethyl tetraisopropyl-phosphorodiamidite, BTT = 5-(benzylthio)-1H-tetrazole.
The phosphoroselenoates were synthesized via oxidative selenium incorporation38, and the
longer phosphoroselenoates were prepared for the antisense study39. Later, the phosphoroselenoates
were used for the structural study by Egli’s group26. This Se-modification is achieved during the solidphase synthesis by a selenizing reagent (such as potassium selenocyanate, KSeCN), replacing iodine. The
synthesis of PSe- modification oligonucleotides was in quantitative yield, especially when the modification site was closed to 5’- end. This type of derivatization also provided oligonucleotide high cytotoxicity.
In their work the DNA crystal structures with phosphoroselenoate modification were determined in high
resolution, which indicated that the selenium modification brought obvious perturbation to the oligonucleotides. Subsequently, several other reagents were also developed to introduce the Se-functionality
into phosphate groups. These reagents include benzothioselenol-3-one40, organometallic reagent

10
O
O

N

DMTrO

O

O

O P
H

NH

O

NH

N Se

O

CN

O

O

N

O

O

O

NH

O

N

DMTrO

O P
Se

O

NH

O
N

O

O

O

NC

O
OAcOPh
OAcOPh

Scheme 1.5 Synthesis of phosphoroselenoate dimer by selenium-cyanoethylphthalimide.
(iPrC5H4)2TiSe541 and selenium-cyanoethylphthalimide42. It is worthy to mention that the seleniumcyanoethylphthalimide was an efficient selenizing reagent with the selenium protected by cyan-oethyl
group. In this way the potential selenium oxidation was prevented (scheme 1.5). Though chemical synthesis can successfully prepare phosphoroselenoates, the synthesized phosphoroselenoates are
diastereomer mixtures. Separation of diastereomers is very challenging and impractical for oligonucleotides containing more than one phosphoroselenoate group. The enzymatic synthesis of
phosphoroselenoates was first developed by Huang’s group, and the diastereomerically pure
phosphoroselenoate oligonucleotides were synthesized enzymatically. Se-dNTP series was chemically
synthesized and the diastereomers were easily separated43. Interestingly, DNA polymerase could well
recognize and incorporate both dNTP diastereomers, thereby synthesizing diastereomerically pure
phosphoroselenoate DNAs. Later, phosphoroselenoate RNAs were also synthesized enzymatically with
diastereomeric Se-NTPs,

-Se-

-Se-

-Se-

-Se-UTP. They were success-

fully incorporated into the hammerhead ribozyme to generate diastereomerically pure RNAs for the
function study44,45. Interesting fact was that, on RNA version, the polymerase could recognize one
diastereomer much faster than the other one. Furthermore, the thymidine triphosphate containing the
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Se-moiety at the 4-position was synthesized as well, and it was recognized by the DNA polymerase as
well as the native TTP46 (scheme 1.6).

Figure 1.3 Enzymatic incorporation of backbone selenium into DNAs. (A) Primer and template sequences. (B) Time-course primer extension using R-Se-TTP I and II (Sp and Rp) on 19% polyacrylamide gel. (C)
Exonuclease III digestion after primer extension.

Figure 1.4 Enzymatic incorporation of ATPaSe into RNA by T7 RNA polymerase. a) The DNA sequences of
the top strand and template. b) Gel electrophoresis analysis of the transcription mixture after 1 h of incubation at 37.8oC.

12

Scheme 1.6 Chemical synthesis of 4-SeTTP and enzymatic synthesis of SeT containing DNAs (5). (a) TMSIm; 1,2,4-triazole-POCl3-Et3N; (b) (NCCH2CH2Se)2/NaBH4, EtOH; (c) 80% acetic acid; (d) POCl3, Me3PO4;
tributylamine (TBA), pyrophosphate, DMF; H2O; (e) 0.05 M K2CO3; (f) template-dependent DNA polymerization.

As talked about above, various types of modified nucleic acids with potential selenium
derivatization are summarized in figure 1.5.
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1.3 Novel Structures and Functions of Selenium Derivatized Nucleic Acids
Since the discovery of the naturally Se-containing tRNAs14, the Se-modification has attracted scientists’ enthusiasm to study its unique properties in biochemical and biological systems. Owing to its K
edge of 0.9795 Å and its signal for multiple wavelength anomalous dispersion (MAD) and single wavelength anomalous dispersion (SAD) analysis, selenium is considered as an ideal anomalous scattering
center in crystal X-ray diffraction, which significantly facilitates crystallographic studies on biological
macromolecules. Since the first successful structural determination of a protein with selenomethionine
(replacing sulfur with selenium) and MAD technique developed by Hendrickson’s laboratory 20 years
ago47, more and more novel protein structures have been determined with the selenomethionine
derivatization48-50. Fortunately, the sulfur substitution with selenium does not cause significant perturbations in protein structures and functions. Thus, it is not surprising that currently over two thirds of the
novel protein structures are determined by the selenomethionine strategy and MAD phasing (RCSB Protein Data Bank)50. Clearly, the selenomethionine and MAD strategies have revolutionized the protein Xray crystallography.
However, it was surprising that oxygen atoms in nucleic acids can also be stably replaced with
selenium without causing significant perturbations in structures and functions. This novel strategy with
selenium-derivatized nucleic acids (SeNA) is changing the X-ray crystallography of nucleic acids and protein-nucleic acid complexes. The classical strategy in nucleic acid crystallography relies on the halogen
derivatization, such as Br or I derivatization51. Unfortunately, the I- or Br-derivatized nucleic acids are
sensitive to light, such as UV and X-ray light. In addition, the modification sites for the halogen incorporations are very limited: primarily the 5-position of deoxyuridine, which may cause unavoidable perturbations in structures and functions52. In comparison, the Se-derivatization of nucleic acids offers better
stability and much more diversities than the halogen-derivatization, since in nucleic acids, there are
many oxygen atoms in different chemical environments. Huang’s laboratory synthesized the first Se-
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containing nucleoside phosphoramidites, and pioneered the chemical and enzymatic syntheses and the
selenium-derivatization of nucleic acids for structure and function studies. Through the collaboration
among Huang, Egli and their co-workers, the first structure of the Se-derivatized nucleic acids was determined via the direct selenium derivatization and MAD phasing53. Over the past several years, many
crystal structures of DNAs, RNAs and protein-nucleic acid complexes have been successfully determined.
This novel Se-derivatization strategy has received more and more attention. It will revolutionize X-ray
crystallography of nucleic acids, protein-nucleic acid complexes, as well as small molecule ligand-nucleic
acid complexes.

Figure 1.6 The global and local structures of the 4-Se-T DNA [(5’-GdUSe-G-SeT-ACAC-3’)2]. (A) The duplex
structure of the modified DNA (2NSK, in cyan) is superimposed over the native (1DNS, in pink). (B) The
comparison of the modified (in green) and native (in cyan) local T4 structures. (C) The Se base pair of T4A5 with the experimental electron density.
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Figure 1.7 The superimposed global and local structures of 6-Se-G containing DNA/RNA duplexes of the
nucleic acid–protein complex. a) The structure of the Se-DNA sequence (2R7Y, in yellow) is superimposed over the corresponding native DNA (2G8U, in grey). b) The structure of the RNA sequence (2R7Y,
in green) is superimposed over the corresponding native (2G8U, in grey). c) The Se-G3/C5 base pair
(2R7Y) with the experimental electron density shows three H-bonds (exo-6-Se/exo-4-NH2, 1-NH/N(3),
and exo-2-NH2/exo-2-O) with bond lengths of 3.48, 3.16, and 2.59Å, respectively.

The crystal structures of the selenium-modified nucleic acids provide lots of useful structural information on nucleic acids. The DNA crystal structures containing 4-Se-T24 and 6-Se-G37 indicated that
the selenium modifications generated no obvious structural perturbation comparing with the native
DNA structures (figure 1.6 and figure 1.7), and that a novel hydrogen bond between the selenium atom
and the amino group (Se…H-N) was formed. In addition, unique structural and functional properties of
the selenium-modified nucleic acids were discovered. The corresponding melting temperature studies
also demonstrated that the selenium functionality at nucleobase didn’t generate obvious perturbations.
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Unexpectedly, we found another useful advantage of the selenium modifications: the crystallization facilitation (figure 1.8), especially by the 2’-Se derivatization. The exciting fact is that with the selenium functionality at the 2’-position of sugar, nucleic acids (especially DNAs) are able to crystallize much
faster under broader buffer conditions and with higher diffraction qualities52. One example is the application of 2’-SeMe-dU. The DNA oligonucleotide (GdU2’-SeGTACAC)2 crystallized in a few days from 20 out
of the 24 buffer conditions, while the corresponding native DNA (GTGTACAC)2 did not crystallize over 2-3
months53,54. The crystallization condition of the native DNA is quite narrow. Obviously, the selenium
derivatization is advantageous.

Figure 1.8 Photos of crystals of the native and Se-derivatized octamers. a) Native octamer, b) Seoctamer, c) Se/Br-octamer sizes of the crystals are ranged from 0.1×0.1 to 0.4×0.4 mm.
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Figure 1.9 Time-course enzymatic digestion of phosphoroselenoate RNA with snake venom
phosphodiesterase I. (a) gel electrophoresis autoradiography; (b) the digestion Vs time plot.

Selenium modifications result in nucleic acids with many additional unique properties, particularly useful in biochemical and biological investigations. For instance, the nucleoside triphosphates
derivatized with selenium at non-bridging α-position of phosphate were synthesized, and their two
diastereomers were separated45. It was demonstrated that only one of these two Se-modified triphosphate diastereomers is a good substrate for T7 RNA polymerase in vitro transcription, while the other
diastereomer is not recognized by the enzyme: neither as a substrate nor an inhibitor44. On contrary,
DNA polymerase recognizes both diastereomers43. The recognition differences of the Se-NTPs and SedNTPs can be used to study the catalysis and substrate interactions of DNA and RNA polymerases. Another discovery is that the Se-hammerhead ribozymes transcribed with the nucleoside 5’-(α-Pseleno)triphosphates could demonstrate a high catalytic activity, up to the native level, and could also
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Figure 1.10 The time-course experiment of incorporating TTP and 4-SeTTP into DNA. (A): the gel electrophoresis; (B): the plot of the TTP and SeTTP incorporation into DNA.

display a low or no activity depending on the Se-modified nucleotides, indicating their participation in
the catalysis. These Se-NTPs offer a useful methodology for rapid screening of ribozymes and other noncoding RNAs. Furthermore, it is found that both phosphoroselenoate DNAs and RNAs resist nuclease
digestion, which is especially useful in developing Se-oligonucleotide therapeutics (figure 1.9). Moreover, the triphosphate with the Se-derivatization at the thymidine 4-postion was also synthesized, recognized by DNA polymerase, and incorporated into DNAs (figure 1.10). The enzymatic incorporation efficiency was as good as native TTP. Interestingly, this replacement of a single oxygen atom with selenium
in the nucleobase generates yellow-colored DNA, which will be used as a unique probe for the enzymatic assay46 (figure 1.11).

Figure 1.11 Yellow-colored DNA generated by DNA polymerization reaction from 4-Se-TTP.
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Due to the selenium toxicity and limitation of investigation strategies, in the past, the selenium
modification was not significantly explored in drug discovery research, compared to the sulfur modification and gene therapy. Since recently selenium has been recognized as an essential element, drug discovery with the selenium modifications becomes an opportunity. There is no reason that all the approaches applied in the S-derivatized gene therapy cannot be applied in the Se-derivatized gene therapy. As an element from the same elemental family as sulfur, selenium-functionalized nucleosides, nucleotides and nucleic acids may possess ideal stabilities, and chemical and biological functions. Furthermore, the special electronic and dimensional characteristics of selenium generate unique advantages,
making SeNA an advanced approach for exploring disease mechanisms and treatments at the atomic
level. As discussed previously, the Se-derivatization of nucleic acids is an advanced tool for structure determination. In Huang’s lab, a ternary complex with 6-Se-G containing DNA, RNA and RNase H protein
was crystallized, and their crystal structure was determined37. This is the first example to solve the protein structure with SeNA facilitation, and it opened a gate for the application of selenium-derivatized
nucleic acids in drug design and discovery. Another advantage of SeNA is its resistance to nuclease in
vivo or in vitro, which is the essential requirement for the oligonucleotide therapy. Similar to the thiomodified antisense oligonucleotides, we have demonstrated recently that the Se-modified nucleic acids,
including the modifications on the backbone, sugar and nucleobase, resist nuclease degradation. It is
believed that this novel SeNA can also play important roles in drug discovery.
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Figure 1.12 Structures of some FDA-approved anti-HIV drugs.
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Another important application of selenium in therapeutic development is the synthesis of nucleoside analogues as potential anticancer, antimicrobial or antiviral drugs. Most of the therapeutic nucleosides contain chemical modifications disrupting nucleic acid synthesis or damage repair. Successful
examples are the compounds used to block the human immunodeficiency virus replication in order to
cure AIDS. The best-known approved drugs (figure 1.12) include 3’-azido-3’-deoxythymidine (AZT), 2’,3’dideoxycytidine (ddC), 2’,3’-dideoxyadenosine (ddA), and 2’,3’-didehydro-3’-deoxythymidine (d4T). Their
efficient synthesis is critical in medicinal chemistry and drug manufacture. Researchers have developed
some seleno-mediated synthesis routes to make reactions simple and efficient. Selenium functionalities
were introduced to the nucleosides, in order to generate 2’, 3’-unsaturated nucleosides. The
phenylselenyl group was the most frequently used. Several laboratories have achieved the syntheses of
the 2’,3’-dideoxy- and 2’,3’-didehydro-2’,3’-dideoxynucleosides55-57. After the synthesis of the 2’phenylselenenyl nucleosides, 2’,3’-unsaturated nucleosides were created by treatment with H2O2 or nBu3SnH. These methodologies offered highly efficient synthesis.
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2.

MATERIAL AND EXPERIMENTAL PART

2.1 Synthesis of 5-Selenium-Thymidine Nucleoside and DNA for Structural and Enzymatic Study
2.1.1

Introduction

Hydrogen bonds are formed between hydrogen-bond acceptors and donors (X-H). In a classical
hydrogen bond, X is an atom with strong electron-negativity (oxygen, nitrogen, etc.). However, recently
hydrogen bonds where X is an atom with weak electron-negativity (e.g., carbon) are gaining more acceptance and importance, for instance carbon in C-H···O=C hydrogen bond58-61. The interactions
between C-H and hydrogen-bond acceptors (electron donors), such as C-H···O=C hydrogen bond in
proteins58, C-H···O=C in uracil crystal59, and C-H···Cl in a guest-host system62, and other nonconventional interactions (such as H···π interaction in RNA)63 have played critical roles in molecular
recognition, catalysis, and DNA duplex stability within chemical and biological systems64-67. Since a negatively charged phosphate group is an excellent electron donor and the phosphorylation and
dephosphorylation are common cellular regulation mechanisms, we investigated whether a C-H (or CH3)
group is capable of forming a hydrogen bond with a phosphate group.
In DNA duplexes52,68,69, the 5-methyl group of thymidine is normally 4-5 Å away from the closest
oxygen (pro-Sp oxygen) of the 5′-phosphate group (O--PO3). In order to extend the CH3 group closer to
the phosphate and to give the CH3 more rotational flexibility at the same time, we inserted an atomic
linker between the methyl group and the C5 carbon of thymidine. If the CH3 and phosphate (O--PO3)
groups are able to form a genuine hydrogen bond, they will be observed in a closer proximity and with
strong electron density between them in a crystal structure. If there is no such stabilizing interaction
between them, the methyl group would prefer to turn away from the phosphate due to the sterichindrance and point into the major groove. Since the size and geometry are essential requirements for
this investigation, we thus inserted a selenium atom as an atomic probe between the 5-methyl group
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and C5 carbon. Herein we report the first synthesis of 5-Se-thymidine phosphoramidite (5, Scheme 2.1),
its chemical incorporation into DNAs, and the biophysical and structural studies of the DNAs containing
the Se-extended 5-CH3. Excitingly, we have discovered a novel methyl/phosphate hydrogen bond
(CH···O--PO3) for the first time.
On the other hand, gene therapies are kinds of important drug molecules, which generate low
toxicity, own high specificity and efficiency. The oligonucleotide drug molecule is supposed to exhibit
some advantages, like specific binding affinity to the target nucleic acid and high stability to nucleases in
vivo5,52. Nucleases, including DNases and RNases, are a class of enzymes that catalyze the hydrolysis of
phosphodiester linkage of nucleic acids, resulting in the degradation of single or double stranded nucleic
acid70. Nucleases’ activity is involved in many biological pathways, such as gene expression regulation in
siRNA and micro-RNA mechanisms71-73 or Okazaki fragment synthesis in genomic DNA replication74. A
crucial cellular role of DNases and RNases is to protect cells from foreign pathogenic DNAs and RNAs.
Thus, stability against endogenous nucleases is a prerequisite property for oligonucleotides based therapeutics, such as antisense-DNA, siRNA, and micro-RNA. Currently the chemical modification is one of
the effective strategies to obtain the high stability under nuclease environment75. Numerous efforts
have been devoted to achieve chemically modified nucleic acid drug molecules, mainly through
derivatizing the sugar and the phosphate backbone moieties, without adversely affecting DNA/DNA and
DNA/RNA duplex formation. For instance, a number of DNA modifications, such as phosphorthioate76,
borano-phosphate77, PNAs78, LNAs79, and certain 2’-sugar modifications, including 2’-OMe80, 2’-ara-F81
and 2’-NH282, are among chemical approaches that showed enhanced DNA or RNA duplex stability
against nuclease digestion. The most successful example is the application of phosphorthioate containing gene therapy, which were approved by FDA as an antiviral drug in 199883,84. However, fewer reports
appear in the literatures that address the correlation of DNAs containing modified nucleobases and the
nuclease resistance of their corresponding duplexes85. Because of the space availability in the major
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groove, a plethora of substituents of different sizes have been tethered at the 5-position of 2’deoxyuridine, and the modified building block has been incorporated into DNA by solid phase synthesis
or enzymatically via the corresponding triphosphate derivatives86-88. In most cases, the wide open space
available in the major groove for the C5 substituent on 2’-deoxyuridine results in DNA/DNA and
DNA/RNA duplexes with higher or comparable thermal stability to the natural DNAs89. Despite of the
broad applications of 5-modified 2’-deoxyuridine containing nucleic acids and the spatial proximity of
the C5-substituents to the phosphodiester linkage90, few studies have reported on their stability against
nuclease digestion. Generally, nucleases use one or more divalent metal cation to activate the scissile
phosphate group and nucleophilic attack by a water molecule. For instance, HincII, a type II endonuclease, utilizes a network of hydrogen bonds between the divalent metal cofactor, glutamate, aspartate
residues, water, and the phosphate group at the enzyme’s active site and thereby facilitate the hydrolysis process of the phosphordiester linkage91. We envisioned that an insertion of a single atom, selenium
(atomic radius 1.16 Å), at the 5-position of thymidine would extend the 5-CH3 group further toward the
scissile phosphate group and disturb the metal cation activation/H2O nucleophilic attack, thereby allowing DNA duplexes with nuclease resistance. The geometry and the free rotation around the 5-Se-CH3
might retard the enzyme–duplex binding, the hydration pattern at the enzyme’s active site and thus interrupt the phosphate hydrolysis. Moreover, the electron donating property of the selenium atom
would potentially enhance the DNA duplex stability by increasing the stacking interaction. These features are important for oligonucleotides based therapies. In addition, our lab’s pioneering research has
shown that the Se-derivatization has a great potential for crystal structure determination of nucleic acids or nucleic acid-protein complex via MAD or SAD phasing9,92. Different from the synthesis above, we
report on the novel synthesis 5-MeSe-2’-deoxyuridine phosphoramidite using lithiating reagent in high
yield (Scheme 2.2), its chemical incorporation into DNAs, and as a proof of principle we demonstrated
their stability against nucleases such as AseI and SalI-endonucleases, and exonuclease III. The thermo
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and structural studies also showed no perturbation was generated by the selenium atom, which is important for the nucleic acid therapy. In order to compare the selenium functionality with other
chalcogen elements, we accomplished the synthesis of DNA with other modifications at 5-position of
thymidine as well, such as MeO-, MeS-, and PhSe-, applying similar strategy. We anticipate that the
thermostability, enzymatic and structural studies of the 5-chalcogen-modified thymidine containing
DNAs can illustrate a potential nucleic acid drug molecule.
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2.1.2

Synthesis Strategy and Structure Determination

The first trial to synthesize the 5-Se-thymidine phosphoramidite (5) started from 3′,5′-di-Obenzyol-2′-deoxyuridine (1)93. Though the arylselenylation at the 5-position of pyrimidines was reported
over a decade ago29, the incorporation of alkylselenyl substitutions (such as CH3-Se) at the 5-position has
not been reported in the literature, probably due to the instability of the alkylselenyl intermediate. After
several attempts of screening Lewis acids as electrophile activators, Mn(OAc)3 was found effective to
promote the methylselenation at the 5-position of 1 with dimethyldiselenide CH3SeSeCH3. Treatment of
1 with CH3SeSeCH3 (in the presence of Mn(OAc)3 in AcOH at 90 °C) gave 5-Sethymidine derivative 2 in
good yield. NMR analysis of 2 showed the disappearance of the H-5 peak and the appearance of the H-6
singlet peak, and displayed the characteristic 1H and 13C chemical shifts of the 5-SeCH3 moiety at 2.06
and 7.24 ppm, respectively. Deprotection of 2 with NaOCH3 in MeOH gave 3 in a quantitative yield. UV
spectrum of 4 shows λ max absorption at 309 nm, red-shifted by 44 nm when compared with thymidine
(Figure 3.1). This large red-shift is caused by the electron-donating effect of 5-SeCH3 on the nucleobase
π-system. Following the tritylation of 3, compound 4 was converted to 5 by the standard
phosphoramidite synthesis.
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Scheme 2.1 Synthesis of 5-Se-T phosphoramidite and oligonucleotides.

Syntheses strategies: a mixture of 3’,5’-di-O-benzoyl-2’-deoxyuridine (1) (1.89 g, 4.35 mmol),
Mn(OAc)3 (3.45 g, 13.0 mmol), and CH3SeSeCH3 (1.23 mL, 13.0 mmol) in glacial AcOH (30 mL) was heated
for 36 h at 90 oC. The mixture was cooled down to room temperature and the insoluble material was
filtered off on a Celitepad, and washed with EtOAc. The filtrate was evaporated, and co-evaporated with
toluene (25mL x 3 times). The residue was purified by flash column chromatography (SiO2: 15 % EtOAc in
CHCl3) to give 2 (1.3 g, 56%) as a white solid, (eluate: 25 % EtOAc in CHCl3) to recover 1 (0.75 g, 40%) as a
white solid. Our NMR analysis showed the disappearance of H-5 peak and appearance of H-6 singlet
peak, and displayed the characteristic 1H and 13C resonance signals 5-SeCH3 moiety of 2 at 2.06 and 7.24
ppm, respectively. Spectral Data for 2: UV λmin= 307 nm (ε = 4700 M-1cm-1 in MeOH), and λmax= 263 nm
(ε = 9650 M-1cm-1 in MeOH); 1H-NMR (CDCl3) δ: 9.29 (1H, s, NH, exchanged with D2O), 8.11-8.03 (4H, m,
Bz), 7.76 (1H, s, H-6), 7.61-7.58 (2H, m, Bz), 7.50-7.45 (4H, m, Bz), 6.42 (1H, dd, H-1’, J = 5.6, J = 8.8 Hz),
5.64 (1H, m, H-3’), 4.78-4.71 (2H, m, H5’a,b), 4.58 (1H, m, H-4’), 2.78 (1H, ddd, H-2’a, J = 1.6, J = 5.6, J =
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14.4 Hz), 2.36 (1H, m, H-2’b), 2.06 (3H, s, SeCH3); 13C-NMR (CDCl3) δ: 166.12 (C=O, Bz), 166.15 (C=O,
Bz), 161.64 (C4), 150.35 (C2), 140.05 (C-6), 133.90 (Ph, Bz), 133.78 (Ph, Bz), 129.97 (Ph, Bz), 129.78 (Ph,
Bz), 129.38 (Ph, Bz), 129.11 (Ph, Bz), 128.90 (Ph, Bz), 128.76 (Ph, Bz), 104.69 (C-5), 85.71 (C4’), 83.16 (C1’), 75.13 (C-3’), 64.51 (C-5’), 38.55 (C2’), 7.24 (SeCH3); HRMS (ESI-TOF): Molecular formula,
C24H22N2O7Se; [M-H]+: 529.0505 (calc. 529.0514).

Figure 2.1 UV spectra of 5-Se-T (red) and thymidine (blue) in MeOH.

To a solution of 2 (0.827 g, 1.56 mmol) in MeOH (10 mL) was added 1M NaOMe in MeOH (1.6
mL). The mixture was stirred for 3 h at room temperature. The mixture was neutralized with Dowex 50
(H+) and the resin was filtered off. The filtrate was evaporated and the residual solid was purified by
flash silica gel column (eluate: 7 % MeOH in CH2Cl2) to give 3 (0.466 g, 93%) as a white solid, which was
crystallized from EtOH: Spectral Data for 3: UV λmax= 309 (ε =2000 M-1cm-1 in MeOH); 1HNMR (DMSO-d6)
δ: 11.52 (1H, s, NH, exchanged with D2O), 7.83 (1H, s, H-6), 6.18 (1H, t, H-1’, J = 6.4 Hz), 5.23 (1H, brd, 3’OH, exchanged with D2O), 5.10 (1H, brt, 5’-OH),4.26 (1H, m, H-3’), 3.80 (1H, m, H-4’), 3.60 (2H, m, H5’a,
H5’b) 2.67(5H, m, H-2’a, H-2’b, and 5-SeCH3); 13C-NMR (CDCl3) δ: 161.70 (C4), 150.06 (C2), 137.61 (C-6),
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104.03 (C-5), 87.53 (C4’), 84.56 (C-1’), 70.40 (C-3’), 61.08 (C-5’), 38.90 (C2’), 5.25 (SeCH3); HRMS (ESITOF): Molecular formula, C10H13N2O5Se; [M]+: 320.9996 (calc. 320.9990).
2’-deoxy-5-methylselenyluridine (3) (0.239 g, 0.74 mmol) was co-evaporated with dry pyridine
(5 mL x 3 times). The dried residue was dissolved in dry pyridine (3 mL) and cooled to 0 oC and treated
with a solution of 4,4’-dimethoxytrityl chloride (0.277 g, 0.82 mmol) in dry pyridine (3 mL). The mixture
was stirred for 3 h at room temperature. The solvent was evaporated and the residue was partitioned
between EtOAc and H2O. The organic phase was dried over MgSO4 and evaporated. The residue was purified by silica gel column chromatography (SiO2 was preequalized with 1% Et3N in CH2Cl2, eluate 4%
MeOH in CH2Cl2) to give (0.380 g, 82%) of 4 as pale yellow foam: 1H-NMR (CD2Cl2) δ: 9.39 (1H, s, NH, exchanged with D2O), 7.90 (1H, s, H-6), 7.46-7.21 (9H, m, DMTr), 6.87-6.84(4H, m, DMTr), 6.29 (1H, dd, H1’, J = 6.4, J = 7.6 Hz), 4.43 (1H, m, H-3’), 4.05 (1H, m, H-4’), 3.68 (6H, 2 s, OMe), 3.30 (1H, dd, H5’a, J =
3.8, J = 10.5 Hz), 3.24 (1H, dd, H5’b, J = 3.6, J = 10.5 Hz), 2.58 (1H, d, 3’-OH), 2.42 (1H, ddd, H- 2’a, J = 3.8,
J = 7.7, J = 10.8 Hz), 2.36 (1H, m, H-2’b), 1.90 (3H, s, SeCH3); 13C-NMR (CD2Cl2) δ: 162.48 (C4), 159.29 (Ar),
150.94 (C2), 145.27 (Ar), 141.81(C-6), 136.21 (Ar), 136.06 (Ar), 130.64 (Ar), 130.62 (Ar), 128.57 (Ar),
128.50 (Ar), 127.47 (Ar), 113.76 (Ar), 104.21 (C-5), 87.33 (CAr3), 86.82 (C4’), 85.89 (C-1’), 72.82 (C-3’),
64.24 (C-5’), 55.78 (OCH3), 41.55 (C2’), 7.44 (SeCH3); HRMS (ESI-TOF): Molecular formula, C31H32N2O7Se;
[M+Na+]+: 647.1274 (calc. 647.1272).
Disopropylethylamine (20 μL, 0.12 mmol) was added to a solution of 4 (0.1 g, 0.16 mmol), 5(sbenzylthio)-1H-tetrazole (0.002 g, 0.008 mmol) and 2-cyanoethyl-N,N,N,N-tetraisopropyl phosphane
(96 mg, 0.32 mmol) in dry CH2Cl2 (5 mL) at 0 oC. The mixture was stirred for 2 h at room temperature
then slowly poured into pentane (100 mL). The produced white precipitate was filtered off, dissolved in
CH2Cl2 (1 mL), and precipitated in pentane. The collected fine powdered white solid was dissolved in
CH2Cl2 and dried under reduced pressure to give 5 (108 mg, 82%) as a mixture of two diasteromers and
was directly used for solid phase synthesis. An analytically pure sample was purified by a preparative TLC
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(eluate: 30% EtOAc in CH2Cl2) to give a mixture of two diasteromers: 1H-NMR (CD3CN, two sets of signals
for a mixture of two diasteromers) δ: 9.16 (1H, s, NH, exchanged with D2O), 7.76 and 7.17 (1H each, s, H6), 7.52-7.22 (9H, m, DMTr), 6.95-6.82 (4H, m, DMTr), 6.19 (1H, dd, H-1’), 4.57 (1H, m, H-3’), 4.10 and
4.05 (1H, m, H-4’), 3.75 (6H, 2 s, OMe), 3.65 and 3.55 (m, CH-ipr), 3.30 (2H, m, H5’a and H5’b), 2.63-2.51
(2H, dd, CH2), 2.47-2.31 (1H, H-2’a and H-2’b), 1.96 (3H, s, SeCH3), 1.17-1.03 (2x 24H, m, CH3-iPr); 13CNMR (CD3CN, two sets of signals for a mixture of two diasteromers) δ: 162.63 (C4), 159.82 (Ar), 151.21
(C2), 146.01 (Ar), 141.65 and 141.57 (C-6), 136.84 (Ar), 136.79 (Ar), 136.73 (Ar), 132.30 (Ar), 131.20
(Ar),131.17 (Ar), 131.15 (Ar), 129.76 (Ar), 129.12 (Ar), 127.98 (Ar), 114.20 (Ar), 104.44 and 104.32 (C-5),
118.80 and 118.38 (CN), 87.52 (CAr3), 86.38 and 86.34 (C4’), 86.14 and 86.08 (C-1’), 74.54 and 74.37 (C3’), 64.41 and 64.23 (C-5’), 59.64 and 59.45 (OMe), 44.15 and 44.03 (C2’), 40.47,40.43, 40.37, 40.32 (CHiPr), 24.99, 24.93 and 24.86 (CH3-iPr), 21.13, 21.06, 20.99 (CH2), 7.09 and 7.05 (SeCH3);
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P-NMR

(CD3CN) δ: 147.95, 147.92; HRMS (ESI-TOF): Molecular formula, C40H49N4O8PSe; [M-H]+: 823.2374 (calc.
823.2375).
Another novel incorporation of selenium derivatization into 5-position of 2’-deoxyuridine was by
using lithiating reagent in high yield (Scheme 2.2), and as a proof of principle we demonstrated their
stability against nucleases such as AseI and SalI-endonucleases, and exonuclease III. The synthesis started from the protection of 3’-hydroxyl group of 5-iodo-5’-DMTr-2’-deoxyuridine (1). After the protection
by TBDMS group, selenyl or thio functionality was introduced into 5-position. Methods available in the
literature for the introduction of non-carbon substitiuents at the 5-position of uridine or 2’-deoxyuridine
include electrophillic addition-elimination to the C5-C6 double bond94, palladium catalyzed nucleophillic
substitution of 5-mercururio derivatives89, and lithiation of 5-halo derivatives in the presence of the
electrophilic species95. The milder reaction condition of the later procedure led us to examine its versatility for the synthesis of the novel 5-methylselenyl-2’-deoxyuridine derivative (5, X=CH3Se, Scheme 2.2).
Lithiation of suitably protected uridine96 and 2’-deoxyuridine97 in the presence of electrophile has been
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reported for the synthesis of variety of 5-substituted pyrimidine nucleosides. However, a common
drawback for these reactions is the formation of the reduction byproduct, deoxyuridine derivatives. A
high C-5/C-6 regioselectivity is observed in the case of uridine derivatives due in part to the steric effects
induced by the 2’-hydroxyl’s protecting group96. For 2’-deoxyuridine derivatives which lacks the 2’hydroxyl group, lithium/halogen exchange of 5-halo-2’-deoxyuridine usually produces high C-5
regioselectivity97. A protection of the N3-imido moiety 5-halo-2’-deoxyuridine is required to eliminate
the N3-H competition for the lithiation agent and thus results in high C5 lithiation yield95,98. We envisioned that applying a transient N3-imido moiety protection of 5-halo-2’-deoxyuridine derivative (2) followed by lithium-halogen exchange and quenching with (CH3)2Se2 would provide efficient access to 5.
Treatment of 5-iodo-2’-deoxyuridine derivative 2 with NaH (1.5 equiv), n-BuLi (2.2 equiv) and excess of
(CH3)2Se2 gave, however, an inseparable mixture of 5-methylselenyl derivative 5 and the corresponding
6-methylselenyl derivative 4 in 7:1 ratio (entry 1, Table 2.1) along with the reduced byproduct derivative
3 (Scheme 2.2). In attempt to improve the C5/C6 regioselectivity, a bulkier lithiating agent, LiHMDS was
utilized (entry 5, Table 2.1), however no lithaition occurred under these conditions. Lithiation using secBuLi, or tert-BuLi gave similar results to n-BuLi in terms of C-5/C-6 regioselectivity (entries 3 and 4, Table
2.1). We next examined the effect of the reaction concentration on the C-5/C-6 regioselectivity, at higher concentration (0.15 M and 0.2 M) with n-BuLi as the lithiating agent (entries 6 and 7, Table 2.1), the
methylselenylation occurred exclusively at the C-5 position, yet the reduced byproduct 3 was isolated in
about 20% yield. Apparently, at higher concentration, the rate of lithium/halogen exchange at the 5position is faster, discouraging the formation of the 6-lithio intermediate and thus results in the observed high regioselectivity. We also found that decreasing the molar equivalence of NaH to (ca. 1.05
equiv) substantially eliminates the formation of the reduced product 3 (entry 8, Table 2.1).
Deprotection of the 3’-TBDMS group of 5 followed by phosphitylation under standard conditions pro-
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vided the building block 7 for solid phase synthesis (Scheme 2.2). Same reaction conditions were applied
as well to introduce CH3S and PhSe groups into 5-position of compound 2.
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Scheme 2.2 Synthesis of 5-chalcogen-T DNAs. Reagents and conditions: a) TBDMSCl, Im., DMF, 4 h, rt, 92
%; b) i) NaH, THF, 15 min, r.t., ii) lithiating agent (table 1), THF, 30 min., -78 °C, iii) X2, 1 h, -78 °C; c)
TBAF, THF, 4 h , rt, 92%; d) i-Pr2NP(Cl)CH2CH2CN, DIEA, CH2Cl2, 1 h, rt, 82%; e) solid phase synthesis.
X=CH3Se, CH3S or PhSe.

Table 2.1 Transient N3 protection and lithium/halogen exchange of 2 in the presence of
dimethyldiselenide.a
b

entry

NaH
(eq.)

lithiating
c
agent (eq.)

1
2
3
4
5
6
7
8

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.05

n-BuLi (3)
n-BuLi (1.2)
sec-BuLi (2.2)
tert-BuLi (2.2)
LiHMDS (3)
n-BuLi (2.2)
n-BuLi (2.2)
n-BuLi (2.2)

concentration
(M)
0.1
0.1
0.1
0.1
0.1
0.15
0.2
0.2

ratio
5:4

d

7:1
10:1
11:1
10:1
-f
35:1
only 5
only 5

e

yield %
5+4
3
71
73
68
65
75
71
85

20
15
23
21
20
19
5

a) All reactions were performed in the presence of 4 equivalents of (CH3)2Se2; b) Deprotonation of the
N3-H was performed at ambient temperature for 30 min; c) Lithium/halogen exchange was performed at
-78 ºC for 30 min. d) The ratio was determined by the integration of the H-1’ of the 1H-NMR of the mixture. e) Isolated yields after silica gel chromatography. f) The starting material was recovered.
Syntheses strategies: the new strategy to synthesize 5-Se-T started from 5-iodo-5’-DMTr-2’deoxyuridine. 3’-position was protected by TBDMS group first to accomplish compound 2. NaH 95%
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(35.5 mg, 1.4 mmol) was added portion wise to a solution of 2 (1.03 g, 1.33 mmol) in dry THF (7 mL) at
room temperature in dry glove box. The mixture was stirred for 30 min until complete cease of hydrogen gas evolution, then cooled down to -78 oC and treated with 1.4 M solution of n-BuLi in hexanes (2.1
mL, 2.93 mmol) was added dropwise over 10 min. The mixture was stirred for 30 min then treated with
(CH3)2Se2 (0.5 mL, 5.32 mmol) and the mixture was further stirred for 1 h at the same temperature. Saturated solution of NH4Cl (5 mL) was added and the mixture was warmed to room temperature.
Ethylacetate was added to the mixture and the whole was washed with H2O, brine, dried over MgSO4,
and evaporated under reduce pressure. The residue was purified by flash silica gel chromatography
(eluate: 20% EtOAc in hexanes) gave 5 (0.83 g, 85%) as a colorless foam. Elution with 25% EtOAc in hexanes gave 3 (45 mg, 5%) as a colorless foam. Spectral Data for 5: 1H-NMR (CDCl3
exchanged with D2O), 7.99 (1H, s, H-6), 7.47-7.22 (9 H, m, Ar), 6.87-6.84 (4H, m, Ar), 6.31 (1H, dd, H-1’, J
= 5.9, J = 7.6 Hz), 4.46 (1H, m, H-3’), 4.02 (1H, m, H-4’), 3.81 (6H, s, CH3O), 3.41 (1H, dd, H-5’a, J = 3.2, J =
10.7 Hz), 3.31 (1H, dd, H-5’b, J = 3.4, J = 10.7 Hz), 2.39 (1H, ddd, H-2’a, J = 2.6, J = 5.8, J = 13.2 Hz), 2.19
(1H, m, H-2’b), 2.05 (9 H, s, tert-Butyl), 0.05 (3H, s, CH3), 0.01 (3H, s, CH3); 13C-NMR (CDCl3
(C4), 150.09 (C2), 141.57 (C-6), 135.60 (Ar), 135.54 (Ar), 130.11 (Ar), 128.12 (Ar), 127.95 (Ar), 127.00
(Ar), 113.28 (Ar), 103.56 (C-5), 86.86 (C4’), 85.55 (C-1’), 72.54 (C-3’), 63.13 (C-5’), 55.25 (OMe), 41.72
(C2’), 25.74 (CMe3),17.95 (CMe3), 7.30 (SeCH3), -4.69 (SiMe2), -4.86 (SiMe2); HRMS (ESI-TOF): Molecular
formula C37H45N2O7SeSi [M-H]+: 737.2147 (calc.737.2161).
A 1 M solution of TBAF in THF (1.55 mL) was added to a solution of 5 (0.75 g, 1.02 mmol) in THF
(15 mL) at 0 oC. The mixture was stirred for 6 h at room temperature. The solvent was evaporated and
the residue partitioned between EtOAc and H2O. The organic phase was dried over MgSO4 and evaporated the residue was purified by silica gel column chromatography (the silica gel was pre-equalized with
1% Et3N in CH2Cl2, eluate 4% MeOH in CH2Cl2) to give (0.58 mg, 92%) of 6 as pale yellow foam: 1H-NMR
(CD2Cl2) 9.39 (1H, s, NH, exchanged with D2O), 7.90 (1H, s, H-6), 7.46-7.21 (9H, m, Ar), 6.87-6.84(4H, m,
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Ar), 6.29 (1H, dd, H-1’, J = 6.4, J = 7.6 Hz), 4.43 (1H, m, H-3’), 4.05 (1H, m, H-4’), 3.68 (6H, 2 s, OMe), 3.30
(1H, dd, H5’a, J = 3.8, J = 10.5 Hz), 3.24 (1H, dd, H5’b, J = 3.6, J = 10.5 Hz), 2.58 (1H, d, 3’-OH), 2.42 (1H,
ddd, H-2’a, J = 3.8, J = 7.7, J = 10.8 Hz), 2.36 (1H, m, H-2’b), 1.90 (3H, s, SeCH3); 13C-NMR (CD2Cl2) 162.48
(C4), 150.94 (C2), 141.81(C-6), 136.21 (Ar), 136.06 (Ar), 130.64 (Ar), 130.62 (Ar), 128.57 (Ar), 128.50 (Ar),
127.47 (Ar), 113.76 (Ar), 104.21 (C-5), 86.82 (C4’), 85.89 (C-1’), 72.82 (C-3’), 64.24 (C-5’), 41.55 (C2’),
7.44 (SeCH3); HRMS (ESI-TOF): Molecular formula C31H32N2O7Se [M+Na]+: 647.1274 (calc. 647.1260).
Disopropyl-ethylamine (20 mL, 0.12 mmol) was added to a solution of 6 (0.3 g, 0.48 mmol), 5benzylthiotetrazole (45.4 mg, 0.24 mmol) and 2-cyanoethyl-N,N,N,N-tetraisopropyl phosphane (288 mg,
0.96 mmol) in dry CH2Cl2 (15 mL) at 0 oC. The mixture was stirred for 2 h at room temperature then
slowly poured into pentane (100 mL). The produced white precipitate was filtered off, dissolved in
CH2Cl2 (1 mL), and precipitated in pentane. The collected fine powdered white solid was dissolved in
CH2Cl2 and dried under reduced pressure to give 324 mg, 82% of 7 as a mixture of two diasteromers and
was directly used for solid phase synthesis. An analytically pure sample was purified by a preparative
TLC (eluate: 30% EtOAc in CH2Cl2) to give a mixture of two diasteromers: 1H-NMR (CD3CN, two sets of
signals for a mixture of two diastero

2O),

7.76 and 7.17 (1H

each, s, H-6), 7.52-7.22 (9H, m, DMTr), 6.95-6.82 (4H, m, DMTr), 6.19 (1H, dd, H-1’), 4.57 (1H, m, H-3’),
4.10 and 4.05 (1H, m, H-4’), 3.75 (6H, 2 s, OMe), 3.65 and 3.55 (m, CH-ipr), 3.30 (2H, m, H5’a and H5’b),
2.63-2.51 (2H, dd, CH2), 2.47-2.31 (1H, H-2’a and H-2’b), 1.96 (3H, s, SeCH3), 1.17-1.03 (2x 24H, m, CH3iPr); 13C-NMR (CD3CN, two sets of signals for a mixture of two diasteromers) 162.63 (C4), 151.21 (C2),
141.65 and 141.57 (C-6), 136.84 (Ar), 136.79 (Ar), 136.73 (Ar), 132.30 (Ar), 131.20 (Ar),131.17 (Ar),
131.15 (Ar), 129.76 (Ar), 129.12 (Ar), 127.98 (Ar), 114.20 (Ar), 104.44 and 104.32 (C-5), 118.80 and
118.38 (CN), 86.38 and 86.34 (C4’), 86.14 and 86.08 (C-1’), 74.54 and 74.37 (C-3’), 64.41 and 64.23 (C-5’),
59.64 and 59.45 (OMe), 44.15 and 44.03 (C2’), 40.47,40.43, 40.37, 40.32 (CH-iPr), 24.99, 24.93 and 24.86
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(CH3-iPr), 21.13, 21.06, 20.99 (CH2), 7.09 and 7.05 (SeCH3); HRMS (ESI-TOF): Molecular formula,
C40H49N4O8PSe; [M-H]+: 823.2403 (calc. 823.2375).
After the synthesis of modified phosphoramidite, all DNA oligonucleotides were synthesized
chemically on a 1.0 μmol scale using an ABI392 DNA/RNA Synthesizer. The concentration of the Senucleoside phosphoramidite was identical to that of the conventional phosphoramidites (0.1 M in acetonitrile). Coupling was carried out using a 5-(benzylmercapto)-1H-tetrazole (5-BMT) solution (0.25 M) in
acetonitrile. The coupling time for the Se-nucleoside phosphoramidite was 25 seconds. The 5’detritylation was done using 3% trichloroacetic acid in methylene chloride. Syntheses were performed
on control pore glass (CPG-500) immobilized with the appropriate nucleoside through a succinate linker
(Glen Research). All the oligonucleotides were prepared with DMTr-on and the phosphoramidites protected with fast deprotection groups on the nucleobases. After synthesis, the Se-DNA oligonucleotides
were cleaved from the solid support and fully deprotected by concentrated ammonia at 55 °C overnight.
The SeNAs were then purified twice by HPLC with DMTr-on and DMTr-off, respectively. The DMTr group
was removed by 3% TCA treatment for 3 minutes, followed by triethylamine neutralization. The prepared
and purified DNA samples were analyzed by analytical HPLC and MALDI-TOF MS.
The UV melting experiments were performed using the samples (2 μM DNA duplexes) dissolved
in the buffer of 50 mM NaCl, 10 mM Na2H2PO4-Na2HPO4 (pH 6.5), 0.1 mM EDTA and 10 mM MgCl2. The
samples were heated to 60 oC and allowed to cool down to room temperature slowly. These experiments
were carried out by Cary 300 UV-Visible Spectrophotometer with a temperature controller at a heating
rate of 0.5 oC/min.
The 2’-Deoxy-2’-methylselenyluridine moiety (dU2’-SeMe) was used to facilitate the crystal growth
of the Se-DNA (5'-G-dU2'-Se-G-5-SeT-ACAC-3', self-complementary) using Nucleic Acid Mini Screen kit
(Hampton Research, with 24 diversified crystallization buffers). The crystals grown in buffer #7 [10% (v/v)
MPD, 12 mM Spermine tetra-HCl (pH 6.0), 80 mM NaCl, 20 mM MgCl2] were used for diffraction data
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collection. X-ray data were collected at beam line X12C in NSLS of Brookhaven National Laboratory. A
number of crystals were scanned to find the one with strong anomalous scattering at the K-edge absorption of selenium. 25% glycerol was used as cryoprotectant while data collection was taken under the liquid nitrogen stream at 99°K. The chosen wavelengths for selenium MAD data are 0.9797, 0.9795, and
0.9400 angstroms. The crystal was exposed 10 seconds per image after one degree rotation, and a total
of 180 images were taken for each data set. The additional reference data sets were collected at 1.10 Å
wavelength and were used for the final structure refinement. All data were processed using HKL2000 and
DENZO/SCALEPACK.
The two positions of the selenium atoms were identified by the heavy atom search scripts provided by CNS. Following the refinement of the selenium positions, the experimental phases were calculated and extended using the MAD phasing procedures in CNS. The initial phased maps were then improved by the solvent flattening and density modification procedure. The model of single strand of DNA
was manually built into the electron density map using O, and then the refinement was carried out. The
refinement protocol includes simulated annealing, positional refinement, restrained B-factor refinement,
and bulk solvent correction. The topologies and parameters for UMS with the selenium at the 2’-position
and the modified T (T5S) with the selenium at the 5-position were constructed and applied. After several
cycles of refinements and the model rebuilding, a number of highly ordered waters were added. The two
selenium atoms are fully occupied. Cross-validation with a 10% test set was monitored during the refinement. The σA-weighted maps of the (2m|Fo| - D|Fc|) and the difference (m|Fo| - D|Fc|) density
maps were computed and used throughout the model building. The final R/Rfree values are 0.210/0.226
with 28 waters (Table II and III). The Se-modified duplex and single-stand structures are presented in Figure 3.1. Instead of turning to the major groove, where the space is available to accommodate the modification on the Se-thymidine, the 5-CH3-Se group points to the backbone phosphate in order to form a
novel hydrogen bond (C-H…O--PO3).
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2.1.3 Chalcogen Modified Oligonucleotides’ Stability to Nuclease
Over 3000 types of restriction endonucleases have been isolated from bacteria and studied in
detail, and a lot of them are commercial available and routinely used in laboratory99. The recognition
site for each restriction endonuclease is variable, usually 4-8 nucleotides long, and mostly palindromic.
Type II restriction enzyme is the most commonly used, requires magnesium as cofactor, and cleaves
within recognition site. In order to study how this 5-position-modified-T can affect efficiency of endonuclease, we chose the type II restriction endonuclease AseI and SalI to manipulate, which have cleavage
sites close to thymidine100,101. The complementary sequence was also designed (Figure 2.2). Exonuclease
is a type of enzyme that cleaves nucleotides step-wise from the end of polynucleotide, and is essential
for the function of polymerase. The repair of DNA in E. coli also requires exonulclease III to remove the
abasic sites. Exonuclease III usually exhibits the functions of 3’-repair diesterase, 3’ =>5’ exonuclease, 3’phosphomonoesterase and ribonuclease activity102. Therefore we also use the designed DNA with modification to test the 5-chalcogen-T’s inhibition to exonuclease III.

A:

AseI: 5’-AT↓TAAT-3’
3’-TA AT↓TA-5’
SalI: 5’-G↓TCGAC-3’
3’-C AGCT↓G-3’

B:
DNA1: 5’-GTGCACTGATCAATTAATGTCGAC-3’
DNA2: 5’-GTGCACTGATCAAXTAATGTCGAC-3’
DNA3: 5’-GTGCACTGATCAATXAATGTCGAC-3’
DNA4: 5’-GTGCACTGATCAATTAAXGTCGAC-3’
DNA5: 5’-GTGCACTGATCAATTAATGXCGAC-3’
DNA6: 5’-GTCGACATTAATTGATCAGTGCAC-3’

Figure 2.2 A) Sequences those endonucleases recognize and cleave. B) The different sequences designed
and synthesized for digestion experiment. Arrow is the cleavage site for endonuclease; X is 5-chalcogenT.
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After the solid phase synthesis and purification of these designed DNAs (same procedure as
mentioned above), both native and modified oligonucleotides were 5'-32P labeled using T4 polynucleotide kinase (New England Biolabs) following manufacture’s recommendations. The γ-32P ATP was removed before the single strand DNA oligonucleotide was annealed with the complementary strand. The
double stranded DNAs were treated with endonucleases AseI and SalI, and exonuclease III following the
manufacture’s recommendations. The reaction samples were analyzed by PAGE gel electrophoresis after
quenched by loading dye. The gels were dried and exposed to film for analysis. Figures in chapter 3 show
the different chalcogen modifications on DNA had different impact on nucleases’ hydrolysis.
We also performed the time-course kinetic experiment to study the inhibition effect of 5chalcogen-T modified DNAs to the nuclease. The same operation was done as metioned above in different time scales. Results showed that when the DNA was derivatized with CH3Se group, the nuclease was
completely inhibited.
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2.2 Synthesis of 2-Selenium-Thymidine DNA and Improved Base Fidelity
2.2.1

Introduction

The base pairs are the contributors to the sequence-dependent recognition of nucleic acids, genetic information storage, as well as high fidelity of DNA polymerase replication and RNA polymerase
transcription. The base hydrogen bonding and stacking also contribute to folding and structure of DNA
and RNA1,103-107. To increase RNA structure and function diversities, wobble base pairs (such as U/G) are
involved in RNAs, including ribozymes and viral and ribosomal RNAs108,109. However, the wobble base
pairing, where T (or U) pairs with G instead of A, reduces specific base-pairing recognition110,111 and
compromises high fidelity of the enzymatic polymerization, especially when G or T on template is modified112-115. The wobble base pairing can increase misrecognition and mis-incorporation during nucleic
acid polymerization116-118.
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Figure 2.3 Native and Se-modified T/A base pair and T/G wobble pair.
Since the T/G wobble pairing (or U/G) is caused by the shift of hydrogen bonding via the 2-exooxygen participation within the base pairs (Figure 2.3) and the 2-exo-oxygen atom is not involved in T/A
(or U/A) base-pairing, the 2-position is critical for the discrimination between T/A and T/G pairs (or U/A
vs U/G). Thus, we hypothesized the discrimination of the wobble base pairs by manipulating the steric
and electronic effects at the 2-exo position. In addition to poor hydrogen-bonding ability, selenium
(atomic radius, 1.16 Å) has much larger radius than oxygen (0.73 Å) and sulfur (1.02 Å) in the same ele-
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mental family. Thus, introduction of a selenium atom at the position 2 can largely increase the electronic
and steric effects, resulting in strong base-pairing discrimination, presumably better than the incorporation of a sulfur atom119,120. This atom-specific selenium substitution of the 2-oxygen of thymidine provides a unique chemical strategy to enhance the base pairing specificity. Furthermore, because of the
non-involvement of the 2-exo-oxygen in T/A paring, its atomic replacement with selenium would most
likely allow the normal T/A pairing while discouraging T/G wobble pairing. Herein we report the first synthesis of the novel 2-Se-thymidine (SeT) derivative, its phosphoramidite, and the Se-DNAs. Moreover, our
biophysical and structural studies of the 2-Se-T DNAs reveal that the bulky selenium atom at the 2position can largely increase the mismatch discrimination (including the wobble pairing discrimination)
while maintaining the SeT/A virtually the same as the native T/A base pair, without significant perturbation. This atom-specific substitution and probing provide a novel tool to investigate specific recognition
of base pairs, which is the basis for high fidelity during replication, transcription and translation.
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2.2.2

Synthesis Strategy, Structure Determination and Thermostability Study

Though the selenium functionality was introduced into the 2-position of uridine over three decades ago121,122, selenium hasn’t been incorporated into the 2-position of thymidine and DNA due to the
synthetic challenges. Following our successful selenium incorporation at the pyrimidine 4-positions via
the C-4 activation and displacement24, our successful synthesis started from the 5’- trityl-protection of 2thiothymidine derivative 1 (Scheme 2.3). In order to activate the 2-thio moiety mildly, we alkylated the
2-thio-functionality of 2 with CH3I to give 3123. Treatment of 3 with freshly prepared NaSeH gave a clean
selenization reaction, and 4 was isolated in 82% yield. The protection of the 2-seleno moiety of 4 was
finally achieved with ICH2CH2CN, giving 5 in 91% yield. Phosphitylation46 of 5 gave Se-phosphoramidite
derivative 6. 2-Se-thymidine (SeT) phosphoramidite 6 was found compatible with the conditions of the
solid-phase synthesis, and the stability of the protected 2-Se-T moiety allows us to successfully synthesize the Se-oligonucleotides using the ultramild protecting groups. The coupling of 6 into DNA is similar
to the native DNA synthesis. The synthesized Se-DNAs were purified and analyzed by HPLC and MS.
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Scheme 2.3 Synthesis of 2-Se-T phosphoramidite (6) and Se-DNA (7). Reagents and Conditions: a) DMTrCl, Pyridine, DMAP, rt; b) DBU, DMF, CH3I; c) Se, NaBH4, EtOH; d) I-CH2CH2CN, i-Pr2NEt, CH2Cl2; e) (iPr2N)2P(Cl)OCH2CH2CN, (i-Pr)2NEt, CH2Cl2; f) Solid-phase synthesis.
Syntheses strategies: 4,4’-Dimethoxytrityl chloride (0.95 g, 2.79 mmol) was added to a solution
of 2-thiothymidine (0.6 g, 2.32 mmol) and DMAP (10 mg) in dry pyridine (6 mL) at O °C. The mixture was
stirred for 6 h at rt, and then MeOH (0.5 mL) was added to the mixture. The solvents were evaporated
under reduced pressure and the residue was partitioned between EtOAc and H2O. The organic phase
was dried (MgSO4) and evaporated. The residue was purified by flash column chromatography (SiO2,
pre-equalized with 1% pyridine in CH2Cl2: 10% EtOAc in CH2Cl2) gave (1.1 g, 85%) of 2 as a colorless foam:
UV (MeOH) λmax=

λmax =224 nm (shoulder); 1H-NMR (CDCl3) 10.35 (1H, br d, NH), 8.64 (2H, m,

Ar), 7.88 (1H, d, H-6, J = 0.8 Hz), 7.42-7.40-25 (9H, m, Ar), 6.94 (1H, t, H-1’ J = 6.4 Hz), 6.85-6.82 (4H, m,
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Ar), 4.61 (1H, m, H-4’), 4.13(1H, m, H-3’), 3.78 (6H, 2 s, OMe), 3.55 (1H, dd, H5’a, J = 2.8, J = 10.8 Hz),
3.39 (1H, dd, H5’b, J = 2.8, J = 10.8 Hz), 2.67 (1H, ddd, H-2’a, J = 4.0, J= 6.0, J = 12.0 Hz), 2.31 (1H, m, H2’b), 1.46 (3H, s, 5-CH3); 13C-NMR (CDCl3): 174.30 (C2), 160.94 (C4), 158.93 (Ar), 149.71 (C6), 144.43 (Ar),
136.68 (Ar), 136.42 (Ar), 135.49 (Ar), 130.25 (Ar), 128.28 (Ar), 128.20 (Ar), 127.37 (Ar), 124.02 (Ar),
116.59 (C-5), 113.49 (Ar), 90.05 (C1’), 87.16 (CAr3), 86.80 (C-4’), 71.57 (C-3’), 63.15 (C-5’), 55.43 (OCH3),
41.33 (C2’), 12.24 (5-CH3); HRMS (ESI-TOF) Molecular formula C31H32N2O6S [M+Na+]+: 583.1883 (calc.
583.1879).
1,8-Diazabicyclo[5.4.0]undec-7-ene (0.4 mL, 2.67 mmol) was added to a solution of 2 (1.0 g, 1.78
mmol) and iodomethane (1.1 mL, 17.8 mmol) in dry N,N-dimethylformamide (6 mL) at 0 °C under Nitrogen atmosphere. The mixture was stirred for 1 hour at 0 °C then ice-H2O (3 mL) was added to the mixture. The mixture was diluted with ethylacetate (30 mL). The organic phase was separated and washed
with water (2x10 mL). The organic phase was dried over MgSO4 and the solvent was removed in vacuo.
The residue was purified by flash column chromatography (SiO2: 4% MeOH in chloroform) to give (0.84
g, 82%) of 3 as a colorless foam: UV (MeOH) λmax 271 nm (shoulder), λmax 235 nm; 1H-NMR (CDCl3): 7.85
(1H, s, H-6), 7.52-7.18 (9H, m, Ar), 6.88-6.74 (4H, m, Ar), 6.24 (1H, dd, H-1’, J = 5.6, J = 7.2 Hz), 4.64 (1H,
m, H-3’), 4.13 (1H, m, H-4’), 3.78 (6H, 2 s, OMe), 3.54 (1H, dd, H5’a, J = 3.2 , J = 10.8 Hz), 3.41 (1H, dd,
H5’b, J = 2.8 , J = 10.8 Hz), 3.2 (1H, br s, 3’-OH), 2.58 (3H, s, 2-SCH3), 2.51 (1H, ddd, H-2’a, J = 2.8, J = 5.6, J
= 13.2 Hz), 2.34 (1H, m, H-2’b), 1.55 (3H, s, 5-CH3); 13C-NMR (CDCl3) 169.94 (C4), 161.08 (C2), 159.04 (Ar),
144.478 (Ar), 135.58 (C-6), 135.52 (Ar), 134.76 (Ar), 130.32 (Ar), 128.36.28 (Ar), 128.27 (Ar), 127.44 (Ar),
113.50 (Ar), 119.28 (C-5), 88.30 (C4’), 87.35 (CAr3), 87.02 (C-1’), 72.31 (C-3’), 63.58 (C-5’), 55.50 (OCH3),
41.96 (C2’), 14.95 (2-SCH3), 13.57 (5-CH3); HRMS (ESI-TOF): Molecular formula C32H35N2O6S [M+H]+:
575.2209 (calc. 575.2216).
An ethanolic solution of NaSeH [generated from Se (0.38 g, 4.28 mmol) and NaBH4 (0.19 g, 5.14
mmol) in absolute ethanol (15 mL) at 0 °C for 30 minutes] was added to 3 (0.80 g, 1.39 mmol) under ni-
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trogen atmosphere. The mixture was stirred at room temperature for 72 hours, and then saturated
aqueous NaCl solution (10 mL) was added followed by ethylacetate (30 mL). The organic phase was separated and washed with aqueous NaCl solution (2x10 mL), H2O (10 mL), dried over MgSO4, and evaporated under reduced pressure. The residue was purified by column chromatography (SiO2: 3% MeOH in
CHCl3) to give (0.7 g, 82%) of 4 as a pale yellow foam: UV (MeOH):

λmax 311 nm,

λmax 226 nm

(shoulder); 1H-NMR (CDCl3) 10.63 (1H, br s, NH), 7.94 (1H, s, H-6), 7.39-7.13 (9H, m, Ar), 7.00 (1H, t, H-1’,
J = 6.4 Hz), 6.84 (4H, m, Ar), 4.62 (1H, m, H-3’), 4.14 (1H, m, H-4’), 3.78 (6H, 2 s, OMe), 3.57 (1H, dd,
H5’a, J = 2.8 , J = 10.8 Hz), 3.40 (1H, dd, H5’b, J = 2.4, J = 10.8 Hz), 2.72-2.67 (2H, m, H-2’ab), 1.39 (3H, s,
5-CH3); 13C-NMR (CDCl3): 173.92 (C2), 160.15 (C4), 158.96 (Ar), 144.35 (Ar), 136.77 (Ar), 135.40 (C-6),
130.27 (Ar), 130.25 (Ar), 130.27 (Ar), 130.25 (Ar), 129.21 (Ar), 128.40 (Ar), 128.29 (Ar), 128.24 (Ar),
118.53 (C-5), 113.55 (Ar), 93.03 (C1’), 87.25 (CAr3), 86.99 (C-4’), 71.75 (C-3’), 63.08 (C-5’), 55.46 (OCH3),
41.46 (C2’), 12.38 (5-CH3); HRMS (ESI-TOF): Molecular formula C31H32N2O6Se [M+Na+]+: 631.1332 (calc.
631.1323).
Disopropylethylamine (0.48 mL, 2.72 mmol) was added to a solution of 4 (0.33 g, 0.54 mmol)
and iodopropionitrile (1.5 g, 8.2 mmol) in dry CH2Cl2 (5 mL) at 0 °C. The mixture was stirred at 0 °C for 30
minutes by which time the starting material was completely consumed. The solvent was removed under
reduced pressure and the residue was partitioned between ethylacetate and H2O. The organic phase
was dried over MgSO4 and the solvent was removed in vacuo. The residue was purified by flash column
chromatography (SiO2: 5% MeOH in CH2Cl2) to give (0.33 g, 91%) of 5 as a colorless glassy solid: UV
λmax

λmax 271 nm (shoulder); 1H-NMR (CDCl3): 7.86 (1H, d, H-6, J = 1.2Hz), 7.40-7.21

(9H, m, Ar), 6.85-6.81 (4H, m, Ar), 6.00 (1H, dd, H-1’, J = 5.6, J = 7.6 Hz), 4.66 (1H, m, H-3’), 4.15 (1H, m,
H-4’), 3.78 (6H, 2 s, OMe), 3.51 (1H, dd, H5’a, J = 2.8, J = 12.8 Hz), 3.46-3.38 (3H, m, H5’a, 2SeCH2CH2CN), 3.17 (1H, br s, 3’-OH), 3.03 (2H, m, 2-SeCH2CH2CN), 2.51 (1H, ddd, H-2’a, J = 2.8, J = 6.0, J =
13.6 Hz), 2.41 (1H, m, H-2’b), 1.49 (3H, d, 5-CH3, J = 0.8 Hz); 13C-NMR (CDCl3) : 169.47 (C2), 159.00 (C4),
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155.76 (Ar), 144.35 (Ar), 135.44 (C-6), 135.36 (Ar), 130.29 (Ar), 128.33 (Ar), 128.26 (Ar), 127.45 (Ar),
120.20 (CN), 119.03 (C-5), 113.55 (Ar), 90.24 (C-1’), 87.33 (C-4’), 87.37 (CAr3), 72.28 (C-3’), 63.56 (C-5’),
55.48 (OCH3), 42.22 (C2’), 23.81 (2-Se-CH2-CH2CN), 19.03 (2-Se-CH2CH2CN); HRMS (ESI-TOF): Molecular
formula C34H36N3O6Se [M+H]+: 662.1780 (calc. 662.1769).
Disopropyl-ethylamine (52 µL, 0.3 mmol) was added to a solution of 5 (0.17 g, 0.26 mmol) and 2cyanoethyl-N,N,N,N-tetraisopropyl phosphane (0.15 g, 0.23 mmol) in dry CH2Cl2 (3 mL) at room temperature under nitrogen atmosphere. The mixture was stirred for 2 hours at room temperature and then
the volatiles were removed under reduced pressure without exposure to air. The residue was precipitated from dry pentane and the precipitate was filtered off, dried under reduced pressure to give (6; 162
mg, 82%), which was directly used for solid phase synthesis: 31P-NMR (CD3CN) : 148.90, 148.95;HRMS
(ESI-TOF): Molecular formula C43H52N5O7PSe [M+Cl]-: 896.2441 (calc. 896.2441).
The thermo-stability experiments were performed using the samples (2 μM DNA duplexes) dissolved in the buffer of 50 mM NaCl, 10 mM NaH2PO4-Na2HPO4 (pH 6.3), 0.1 mM EDTA, and 10 mM
MgCl2. These DNA samples were heated to 85 oC and allowed to cool down to 5 oC slowly. These experiments were carried out by Cary 300 UV-Visible Spectrophotometer with a temperature controller at a
heating rate of 0.5 oC/min. The thermal dynamic parameters were calculated through curve fitting by
Meltwin 3.5 (http://www.meltwin.com).
The purified Se-DNA oligonucleotide [1 mM, (G2’SedUGSeTACAC)2] was heated to 70 °C for 2 minute and cooled down slowly to room temperature. Both the native buffer and Nucleic Acid Mini Screen
Kit (Hampton Research) were applied to screen the crystallization conditions at different temperatures
using the hanging drop method by vapor diffusion. The best crystals and data set for this sample were
from the Hampton buffer No.9 (10% v/v MPD, 40 mM Na-cacodylate, pH 6.0, 12 mM spermine tetraHCl, 80 mM sodium chloride, 12 mM potassium chloride, 20 mM magnesium chloride). The crystals were
crystallized in rhombic space group P61, as the same as one of the common packing patterns of this
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octomer sequence. Similar to our previous work, in the presence of the 2’-SeMe modification in the DNA
sequence, the crystals could grow to an average size (0.05x0.05x0.05 mm) within one week at low temperature (10 °C). 30% glycerol, PEG 400 or the perfluoropolyether was used as a cryoprotectant during
the crystal mounting, and data collection was taken under the liquid nitrogen stream at 99 °K. The SeDNA crystal data were collected at both beam lines X12B and X12C in NSLS of Brookhaven National Laboratory. A number of crystals were scanned to find the one with strong anomalous scattering at the Kedge absorption of selenium. The distance of the detector to the crystals was set to 150 mm. The wavelengths of 0.9795 Å was chosen for selenium SAD phasing. The crystals were exposed for 10 to 15 seconds per image with one degree oscillation, and a total of 180 images were taken for each data set. All
the data were processed using HKL2000 and DENZO/SCALEPACK. The structure of the Se-DNA was
solved by molecular replacement with both CNS and Phaser. The refinement protocol includes simulated
annealing, positional refinement, restrained B-factor refinement, and bulk solvent correction. The stereo-chemical topology and geometrical restrain parameters of DNA/RNA have been applied. The topologies and parameters for 2-Se-thymidine (U2S) were constructed and applied. After several cycles of
refinement, a number of highly ordered waters were added. Final, the occupancies of selenium were
adjusted. Cross-validation with a 5-10% test set was monitored during the refinement. The A-weighted
maps of the (2m|Fo| - D|Fc|) and the difference (m|Fo| - D|Fc|) density maps were computed and
used throughout the model building.
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2.3 Synthesis of 5’-Selenium-Thymidine DNA and Convenient Fluorescence Labeling
2.3.1

Introduction

Labeled nucleic acids (DNAs and RNAs) are useful for biochemistry, molecular biology, life sciences and drug discovery124-126. The classical approaches for nucleic acid labeling include the radioactive
labeling, the non-covalent intercalator binding, such as staining with fluorescent dyes (e.g., ethidium
bromide or oxazoles)127,128, and the covalent nucleic acid labeling with a fluorescent dye at the sugar,
phosphate or nucleobase129,130. Since several dye-labeled phosphoramidites are commercially
available131,132, DNA and RNA can be labeled during the solid-phase synthesis by using these expensive
dye-modified phosphoramidites. Alternatively, the post-synthetic labeling is another approach, where
nucleic acids are first modified with a nucleophilic functionality (such as an amino or thiol group133,134)
during the solid-phase synthesis, followed by a reaction of the nucleophile with an activated label (such
as a dye) containing a good leaving group (e.g., bromo or iodo group). Since the incorporated label is not
exposed to the chemical synthesis conditions (such as oxidant, acid and base treatments), the postsynthetic modification can allow incorporation of much broader functionalities, especially labile
ones135,136.
Although tremendous progresses have been made in the post-synthetic labeling of nucleic acids137, several challenges remained. For instance, its selectivity may be compromised due to the presence of many other nucleophiles (e.g., phosphate groups) in nucleic acids. Furthermore, its labeling efficiency is generally low due to the rapid deactivation of the activated labels (e.g., Br-activated dye138) in
aqueous solutions. Thus, there are increasing demands in developing novel strategies for the postsynthetic labeling. Since a selenol (R-SeH) is an excellent nucleophile (better than amino or thiol group),
we expected that a selenol might facilitate the labeling and increase both the selectivity and efficiency.
Therefore, we decided to incorporate a selenium atom onto the 5’-position of an oligonucleotide by replacing the 5’-oxygen atom (Scheme 2.4).
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Our laboratory pioneered the atom-specific substitution of oxygen with selenium for the structural and functional studies of nucleic acids21. Our previous investigations of the selenium replacements
at the base, sugar or backbone indicate that the modified oligonucleotides did not show significant
structural and functional perturbations after the selenium derivatization24,37,46. Since the 5’-terminal labeling is unlikely to cause any perturbations in a duplex and a polymerase extension reaction; we replaced the 5’-oxygen with selenium, offering a selenol as the nucleophile for the labeling. We describe
here a straightforward synthesis of the 5’-Se-modified thymidine, its corresponding Se-phosphoamidite,
and the Se-DNA. We have also demonstrated the proof of principle by showing that a fluorescent dye
can be successfully incorporated into the DNA via the 5’-Se-functionality. Furthermore, we found that
DNA polymerase can efficiently recognize the dye-labeled Se-DNA.

Scheme 2.4 Synthesis of the 5’-Se-DNA and labeled-DNA. a) p-toluenesulfonyl chloride, pyridine; b) di-2cyanoethyl diselenide, NaBH4, ethanol, THF; c) pyridinium trifluoroacetate, bis(diisopropylamino)
cyanoethyl phosphoramidite, acetonitrile; d) solid-phase synthesis; e) activated dye, K2CO3 in MeOH.
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2.3.2

Synthesis Strategy and Biofunctional Study

The synthesis of this novel 5’-Se-thymidine started from the activation of thymidine (1) at the 5’
position by a toluenesulfonyl group (Scheme 2.4). This activating group was substituted by the
cyanoethyl selenide, which was generated by reduction of di-2-cyanoethyl diselenide139. The protected
Se-functionality was introduced in 89% yield, followed by converting 2 into its corresponding
phosphoramidite (3, mT) in 80% yield. This 5’-Se-derivatized phosphoramidite (mT) was then incorporated into oligonucleotide chemically on solid phase. The ultra-mild phosphoramidites were used for the
synthesis because of the requirements of the Se-functionality deprotection and the labeling25,140. The
coupling yield of this Se-modified phosphoramidite was satisfactory. After the full deprotection and dye
labeling under a mild condition (MeOH solution of K2CO3), the synthesized dye-labeled and non-labeled
DNAs were analyzed by HPLC, UV and MS to confirm their integrity.
Syntheses strategies: thymidine 3.14 g (MW 242.23, 12.9 mmol) was dissolved in pyridine 15
ml, the solution of p-toluenesulfonyl chloride 2.47 g (MW 190.65, 1 eq) in pyridine 5 ml was added
dropwise in 0 ℃. The reaction continued for overnight. After the reaction was completed (monitored by
TLC, 5% MeOH in CH2Cl2, Rf =0.3), the solution was co-evaporated with toluene for several times to get
the white solid. Dissolve the crude product in Ethanol by heating and recrystalized for several times to
get the pure white solid product 5’-toluenesulfonyl-thymidine 4.4 g (yield =86%).
5’-toluenesulfonyl-thymidine 681 mg (MW 396.1, 1.72 mmol) was dissolved in THF 5 ml. NaBH4
260 mg (MW 37.8, 4 eq) was dissolved in EtOH 3 ml, and this solution was injected into the flask containing EtOH solution of di-2-cyanoethyl-selenide 1.37 g (MW 266, 3 eq). After the injection, the yellow
solution of di-2-cyanoethyl-selenide became colorless and the sodium 2-cyanoethyl-selenide
(NCCH2CH2SeNa) was generated. This sodium 2-cyanoethyl-selenide reagent was added to the solution
of 5’-toluenesulfonyl-thymidine, reacted for 3 h, and the reaction was monitored by TLC (5% MeOH in
CH2Cl2, Rf =0.25). After reaction was done, the solution was neutralized by acetic acid and evaporated
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under reduced pressure. The crude product was purified by fresh silica gel column chromatography using MeOH in CH2Cl2 (0, 0.5%, 1%… 200 ml each) to get the pure product 5’-(2-cyanoethyl)selenothymidine 2 550 mg as a white foam (yield =89%). 1H-NMR (400 MHz, DMSO) δ: 1.80 (s, 3H, CH3), 2.032.09 (m, 1H, H-2’), 2.20-2.27 (ddd, J= 6.4 Hz, 1H, H-2’), 2.75-2.86 (m, 2H, H-5’), 2.90-2.93 (t, J= 6.8 Hz, 2H,
CH2CN), 2.93-2.98 (t, J= 6.8 Hz, 2H, SeCH2), 3.87-3.91 (m, 1H, H-3’), 4.14-4.16 (m, 1H, H-4’), 5.37 (s, 1H,
OH), 6.16-6.20 (t, J= 6.8 Hz, 1H, H-1’), 7.49 (s, 1H, H-6), 11.31 (s, 1H, NH). 13C NMR (100 MHz, DMSO) δ:
14.43 (CH3), 19.26 (CH2CN)), 27.44 (SeCH2), 38.49 (C-2’), 45.17 (C-5’), 73.42 (C-3’), 84.31 (C-4’), 86.39 (C1’), 110.32 (C-5), 120.53 (CN), 136.41 (C-6), 150.94 (C-2), 164.14 (C-4). HR-MS (ESI-TOF, negative ion
mode): molecular formula: C13H17N3O4Se; [M-H]-: 358.0297 (calc. 358.0384).
5’-(2-cyanoethyl)seleno-thymidine 400 mg (MW 359, 0.88 mmol) was dissolved in CH3CN 5 ml,
pyridinium trifluoroacetate (MW 193, 1.5 eq, 252 mg) and bis(diisopropylamino)cyanoethyl
phosphoramidite (MW 301.4, 1.5 eq, 100.7mg) were added sequently. The reaction was performed at
room temperature for 2 hours and the reaction was monitored by TLC (30% EtOAc in CH2Cl2, Rf =0.70
and 0.66, two diastereoisomers). After the reaction was completed, the solution was directly loaded on
the silica gel column chromatography, which was equilibrium by 1% triethyl amine in CH2Cl2. The product was eluded by EtOAc in CH2Cl2 (10%, 20% …, 200 ml each) to give the product 5’-(2cyanoethyl)seleno-thymidine 3’-O-(2-cyanoethyl)diisopropylamino phosphoramidite 3 360 mg. (yield=
68%) 1H-NMR (400 MHz, CDCl3, two sets of signals from a mixture of two diastereomers) δ: 1.32 and
1.34 (2x s, 24H, 8x CH3-ipr), 1.64 (2x s, 6H, 2x CH3), 1.91-1.92 (2x t, J= 1.2 Hz, 6H, 2x OCH2CH2CN), 2.322.40 and 2.50-2.61 (2x m, 4H, 2x H-2’), 2.72-2.75 and 2.81-2.84 (2x t, J= 6.0 Hz, 4H, 2x SeCH2CH2CN),
2.81-2.84 (m, 4H, SeCH2CH2CN), 2.86-2.91 (m, 4H, 2x H-5’), 3.04-3.06 (m, 4H, 2x CH-ipr), 3.33-3.40 (2x t,
J= 6.4 Hz, 4H, 2x OCH2CH2CN), 4.07-4.11 (m, 2H, 2x H-4’), 4.81-4.82 and 4.90-4.91 (2x m, 2H, 2x H-3’),
6.18-6.26 (2x t, J= 6.0 Hz, 2H, 2x H-1’), 7.22 and 7.23 (2x s, 2H, 2x H-6), 8.97 and 8.98 (2x s, 2H, 2x NH) 13C
NMR (100 MHz, CDCl3, two sets of signals from a mixture of two diastereomers) δ: 11.81 and 11.85
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(CH3), 19.03 and 19.12 (SeCH2CH2CN), 19.37 and 19.43 (OCH2CH2CN), 19.76 and 19.83 (SeCH2CH2CN),
23.94 and 24.24 (CH3-ipr), 25.92 and 26.06 (C-2’), 44.58 and 44.64 (CH-ipr), 57.20 and 57.29
(OCH2CH2CN), 57.42 and 57.47 (C-5’), 74.18 and 74.34 (C-3’), 74.62 and 74.77 (C-4’), 83.58 and 83.72 (C1’), 110.87 and 110.92 (C-5), 116.98 and 117.08 (OCH2CH2CN), 117.98 and 118.12 (SeCH2CH2CN), 134.81
and 134.96 (C-6), 149.33 and 149.39 (C-2), 162.62 (C-4) 31P NMR (162 MHz, CDCl3) δ: 148.77 HR-MS (ESITOF, negative ion mode): molecular formula: C22H34N5O5PSe; [M-H]-: 558.1368 (calc. 558.1463).
In order to simplify the labeling strategy, it is desired to achieve the simultaneous labeling and
deprotection in one pot, i.e., using the deprotecting reagent and the activated label (e.g., dye) at the
same time. Before finally establishing the labeling strategy, we attempted several approaches and reagents, including stronger bases [e.g., NH3 and 1,8-diazabicycloundec-7-ene (DBU)] and various polar solvents (e.g., DMF, DMSO, and MeOH). The activated dye was deactivated by a reactive deprotecting reagent (a stronger base), which might be the main reason that our early one-pot trials failed. On the other
hand, the protecting groups of the nucleobases will not be completely removed, if a less-reactive
deprotecting reagent (a weaker base) is used. Later, we found compatible conditions for both the
deprotection and labeling in one step, when the ultra-mild phosphoramidites were used. Because the 5’Se-functionality is protected with a base-labile group, we can simultaneously remove the protecting
groups of the Se-moiety and nucleobases. The generated selenol (R-SeH) or selenide anion (R-Se-) is
then alkylated by the activated dye in the reaction. Finally, we achieve the post-synthetic labeling by just
adding the activated dye (e.g., 5-Iodoacetamido-fluorescein, 5-IAF) during the deprotection step, easily
resulting in the dye-labeled DNA.
To demonstrate the usefulness of our novel strategy for DNA labeling, we performed a DNA
polymerization reaction by using the fluorescein-labeled DNA as a primer. After the polymerization and
gel electrophoresis, the gel was visualized by shining with blue light (450-490 nm). A time-course experiment of DNA polymerization reaction was performed and directly visualized, while the corresponding
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experiment using the non-labeled DNA was handled in the same way. The full-length product with the
labeled dye was also confirmed by MS analysis.
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2.4 Synthesis of 5-Selenium-Cytidine DNA for Structural and Enzymatic Study
2.4.1

Introduction

5-methylcytosine (m5C), which is being recognized as the fifth nucleobase of genomic DNA, has
attracted tremendous research interest since its first discovery over six decades ago141-144. m5C is generated via the methylation of cytosine in both prokaryotes and eukaryotes by DNA-cytosine
methyltransferases (DNMTs). Though it is a minor base in mammalian and plant genomic DNA (about
1%-6%141,145), 5-methylcytosine carries additional inheritable information besides its regular function as
cytosine in genomic DNA. The cytosine 5-methylation is a key epigenetic event in vivo to maintain genome integrity146 and regulate gene expression147. It is also known that m5C often exists in repetitive
DNA elements, such as dinucleotide CpG islands148, and m5C in transposons is able to reduce the damage and stability threat to the host genome149. Furthermore, the cytosine methylation is essential for Xchromosome inactivation, resulting in the gene expression silencing in female150. Since most of the
monoallelic expression of imprinted genes also depends on m5C, the methylation in CpG islands normally causes asymmetric expression from only one of two identical alleles151. In some somatic cells, m5C in
promoters often contributes to the regulation of gene expression by influencing the interaction between
transcriptional regulators and cognate DNA152. Moreover, the abnormal hyper-presence of m5C may
activate oncogenes, cause silencing of tumor suppressor genes, and contribute to tumorigenesis, thereby playing a critical role in the etiology of human cancers153.
Considering the fact that such minor chemical modification at 5-position of cytosine can cause
tremendous functional alterations, we decided to synthesize and investigate the cytosine 5-methylation
by derivatizing the exo-5-position of cytosine via insertion of a selenium atom between the 5-methyl
group and pyrimidine. On the basis of our previous research, selenium can afford nucleic acids with
many unique properties for structure and function studies9,25,154. Thus, by tailoring the electron density
and steric effect at the 5-position of 5-Me-cytosine, this selenium modification will likely provide novel
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insights into the cytosine 5-methylation. Furthermore, the SeC modification offers a stable and useful
selenium derivatization for nucleic acid X-ray crystallography23,92, since selenium-derivatized nucleic acids (SeNA) can facilitate crystallization and phasing. Herein we report the synthesis of SeC, its
phosphoramidite and SeC-DNAs, and biophysical and structural studies of the Se-DNAs.
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2.4.2

Synthesis Strategy and Structure Determination

The synthesis (Scheme 2.5) of 2’-deoxy-5-(methylselenyl)cytidine started from the protected
deoxyuridine (1), and the 5-seleno-thymidine analog (2) was synthesized by following our previous report. To convert the thymidine analog to the cytidine derivative, 2 was activated by triisopropylbenzenesulfonyl (TIPS) group, followed by ammonium treatment. Initially, we attempted to isolate the TIPSactivated thymidine, unlike the corresponding purine analogue, the TIPS-activated thymidine derivative
is not stable and decomposed during silica gel chromatography. Finally, we developed the one-pot reaction to synthesize the 5-Me-Se-deoxycytidine without purification of the intermediate. After the 4-NH2
protection and the 2’-hydroxyl group deprotection, Compound 4 was converted to the 5-Me-Sedeoxycytidine phosphoramidite (5) in high yield. It was found that this selenium functionality is stable
under the synthetic conditions (including strong base, fluoride treatment, I2 oxidation, and strong acid
treatments) and purification.
Syntheses strategies: after 5-methylseleno-3’-t-butyldimethylsilyl-5’-O-(4,4-dimethoxytrityl)-2’deoxyuridine90 (480 mg, MW 752.2, 0.64 mmol) was dissolved in acetonitrile 10 mL, diisopropylethyl
amine (0.67 mL, 3.19 mmol, 5 eq.), triisopropylbenzenesulfonyl chloride (576 mg, 1.59 mmol, 2.5 eq.)
and p-dimethylamino pyridine (96 mg, 0.64 mmol, 1 eq.) were added sequentially. The reaction mixture
was stirred for 16 hours and monitored on TLC (ethyl acetate/hexane, 3:7). After completion, excessive
concentrated ammonium hydroxide solution was added dropwise and the reaction was stirred under
room temperature for 1 hour. After the reaction was completed (monitored on TLC, 5% MeOH in CH2Cl2,
Rf =0.5), the organic solvent and ammonium hydroxide were evaporated under reduced pressure. A silica gel column was equilibrated with CH2Cl2 before the crude product was loaded and purified on the
column. The product was eluded by MeOH in CH2Cl2 (1-7%). The fractions containing the product were
combined, evaporated and dried on high vacuum overnight to yield a yellow solid (307 mg, yield= 64%).
1

H-NMR (400 MHz, DMSO) δ: 0.05 (s, 6H, SiCH3), 0.87 (s, 9H, t-butyl), 1.95 (s, 3H, SeCH3), 2.18-2.25 and
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2.58-2.62 (2x m, 2H, H-2’), 3.30-3.33 and 3.46-3.49 (2x m, 2H, H-5’), 3.84 (s, 6H, 2x OMe), 4.03-4.08 (m,
1H, H-3’), 4.42-4.46 (m, 1H, H-4’), 6.11 (s, 1H, NH2), 6.28-6.31 (t, J= 5.6 Hz, 1H, H-1’), 6.50 (s, 1H, NH2),
6.86-7.48 (m, 13H, arom-H), 8.30 (s, 1H, H-6). 13C NMR (100 MHz, DMSO) δ: -4.86 and -4.69 [Si(CH3)2],
7.31 (SeCH3), 17.96 [SiC(CH3)], 25.74 [SiC(CH3)], 41.74 (C-2’), 55.26 (OMe), 62.88 (C-5’), 72.23 (C-3’),
85.55 (C-4’), 87.05 (arom-C), 87.16 (C-1’), 103.45 (C-5), 113.23 (arom-C), 126.94 (arom-C), 128.15 (aromC), 130.11 (arom-C), 135.50 (arom-C), 141.74 (C-6), 144.41 (arom-C), 149.89 (C-2), 155.46 (arom-C),
158.66 (C-4), 161.46 (arom-C), 165.55 (arom-C). HR-MS (ESI-TOF, possitive ion mode): molecular
formula, C37H47N3O6SeSi: [M+H+]+: 738.2468 (calc. 738.2478).
5-methylseleno-3’-t-butyldimethylsilyl-5’-O-(4,4-dimethoxytrityl)-2’-deoxycytidine (300 mg, MW
751.3, 0.4 mmol) was placed in a flask and dried on high vacuum for one hour before addition of anhydrous pyridine 10 mL. Benzoyl chloride 0.03 mL (0.6 mmol, 1.5 eq.) was added dropwise before the reaction solution was stirred for 1 hour. After the reaction was completed (monitored on TLC, 30% ethyl acetate in hexane, Rf= 0.5), the crude product was extracted with saturated NaCl solution and ethyl acetate.
The organic phase was removed and aqueous phase was extracted with ethyl acetate three times. The
combined organic phase was dried over anhydrous MgSO4, the salt was filtered, and the organic solvents
were evaporated under reduced pressure. The residue was purified on a silica gel column (equilibrated
with hexane) and eluted with an ethyl acetate/hexane gradient (EtOAc in hexane, 10-50%). Compound 3
was isolated and dried to afford a yellow-green solid (287 mg, yield= 84%). 1H-NMR (400 MHz, DMSO) δ:
0.09 and 0.04 [2x s, 6H, Si(CH3)2], 0.86 (s, 9H, t-butyl), 2.02 (s, 3H, SeCH3), 2.18-2.20 and 2.43-2.52 (2x m,
2H, H-2’), 3.29-3.33 and 3.43-3.46 (2x m, 2H, H-5’), 3.81 (s, 6H, 2x OMe), 4.05-4.08 (m, 1H, H-3’), 4.414.45 (m, 1H, H-4’), 6.30-6.34 (t, J= 6.4 Hz, 1H, H-1’), 6.86-7.56 (m, 18H, arom-H), 7.88 (s, 1H, NH), 8.32 (s,
1H, H-6). 13C NMR (100 MHz, DMSO) δ: -4.89 and -4.69 [Si(CH3)2], 1.03 (SeCH3), 17.95 [SiC(CH3)], 25.73
[SiC(CH3)], 41.86 (C-2’), 55.26 (OMe), 63.05 (C-5’), 72.41 (C-3’), 86.30 (C-4’), 86.77 (C-5), 87.24 (C-1’),
113.27 (arom-C), 127.07 (arom-C), 128.13 (arom-C), 128.27 (arom-C), 129.38 (arom-C), 130.09 (arom-C),
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132.67 (arom-C), 133.68 (C-6), 135.51 (NHCO), 144.41 (arom-C), 144.36 (C-2), 158.69 (C-4). HR-MS (ESITOF, negative ion mode): molecular formula, C44H51N3O7SeSi: [M-H+]-: 840.2570 (calc. 840.2583)
4-N-benzoyl-5-methylseleno-3’-t-butyldimethylsilyl-5’-O-(4,4-dimethoxytrityl)-2’-deoxycytidine
(3, 280 mg, MW 855.3, 0.33 mmol) was placed in a flask and dried under high vacuum before it was dissolved in anhydrous THF. The solution was placed in an ice-water bath under dry argon. tetraButylammonium fluoride 0.44 mL (1M solution in THF, 1.2 eq.) and acetic acid 0.03 mL (1.2 eq.) were
injected dropwise simultaneously to make solution pH keep about 7. The reaction mixture was stirred for
overnight before it was completed (monitored on TLC, 3% methanol in dichloromethane, Rf= 0.35). The
crude product was extracted by EtOAc and NaCl solution (sat.) three times, and the combined organic
layer was dried over anhydrous MgSO4, followed by filtration and solvent evaporation. The residue was
purified on a silica gel column (equilibrated with CH2Cl2) and eluted with a methanol/dichloromethane
gradient (0.5-5%) to afford the desired product 4 (225 mg, yield= 91%). 1H-NMR (400 MHz, DMSO) δ:
2.04 (s, 3H, SeCH3), 2.21-2.26 and 2.69-2.76 (2x m, 2H, H-2’), 3.34-3.47 (2x m, 2H, H-5’), 3.79 (s, 6H, 2x
OMe), 4.15-4.17 (m, 1H, H-3’), 4.46-4.48 (m, 1H, H-4’), 6.14-6.17 (t, J= 6.4 Hz, 1H, H-1’), 6.84-7.79 (m,
18H, arom-H), 8.48 (s, 1H, H-6). 13C NMR (100 MHz, DMSO) δ: 11.02 (SeCH3), 41.99 (C-2’), 55.27 (OMe),
63.11 (C-5’), 72.41 (C-3’), 86.67 (C-4’), 86.94 (arom-C), 87.87 (C-1’), 102.39 (C-5), 113.31 (arom-C), 127.07
(arom-C), 128.04 (arom-C), 128.07 (arom-C), 128.29 (arom-C), 129.68 (arom-C), 129.45 (arom-C), 130.00
(arom-C), 130.92 (arom-C), 132.70 (arom-C), 134.22 (arom-C), 135.47 (NHCO), 144.41 (arom-C), 144.32
(C-2), 150.83 (C-6), 158.69 (C-4), 172.28 (arom-C). HR-MS (ESI-TOF, possitive ion mode): molecular
formula, C38H38N3O7Se: [M+H+]+: 728.1898 (calc. 728.1797).
4-N-benzoyl-5-methylseleno -5’-O-(4,4-dimethoxytrityl)-2’-deoxycytidine (4, 200 mg, MW 741.2,
0.27 mmol) was placed in a 25 mL round flask and dried on high vacuum. Dry CH2Cl2 3 mL, N,Ndiisopropylethylamine 0.06 mL (0.4 mmol, 1.5 eq.) and 2-cyanoethyl N,N-diisopropylchloro
phosphoramidite 80 mg (0.4 mmol, 1.5 eq.) were then added sequentially. The reaction mixture was
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stirred at room temperature for 2 hours, and the reaction completion was indicated by TLC (3%
MeOH/CH2Cl2, Rf = 0.37 and 0.38, two diastereomers). The reaction was then quenched with NaHCO3
(sat.) and extracted with CH2Cl2 three times, and dried over anhydrous MgSO4, followed by filtration and
solvent evaporation. The crude product was re-dissolved in CH2Cl2 (3 mL) and this solution was added
dropwise to pentane (200 mL) under vigorous stirring to yield yellow precipitate. The pentane solution
was decanted carefully (sometimes filtration was necessary) and the crude product was loaded into a
silica gel column that was equilibrated with CH2Cl2 containing 1% triethylamine. The product was eluted
with an increasing stepwise gradient of MeOH/CH2Cl2 in the presence of 1% triethylamine (1-5%). The
fractions containing target compound were combined evaporated under reduced pressure to afford a
yellow solid (216 mg, yield= 85%).
The Se-DNA oligonucleotides were synthesized by solid-phase synthesis using an ABI392
DNA/RNA synthesizer on a 1 μmol scale. The concentration of the Se-modified cytidine phosphoramidite
(5) was identical to that of the standard phosphoramidite (0.1 M in acetonitrile). The coupling reaction
was carried out using a 5-BTT solution (0.25 M) in acetonitrile with a coupling time of 25 seconds. All the
oligonucleotides were synthesized with DMTr-On, followed by the cleavage from the CPG solid support
(beads) and the deprotection with concentrated ammonia solution under 55 ºC over night. After the
DMTr-on purification by HPLC, the detritylation of the oligonucleotides was performed by the treatment
of 3% trichloroacetice acid (aqueous solution) for five minutes, followed by neutralization to pH 7.0 with
triethylamine and extraction with petroleum ether to remove the by-product DMTr-OH. The DMTr-off
oligonucleotides were purified again by HPLC.
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Scheme 2.5 Synthesis of the 2’-deoxy-5-(methylselenyl)cytidine phosphoramidite and its oligonucleotide. a) TIPS-Cl, DIEA, DMAP, acetonitrile; b) conc. NH3H2O; c) Bz-Cl, pyridine; d) TBAF, acetic acid, THF; e)
2-cyanoethyl N,N-diisopropylchloro-phosphoramidite, DIEA, CH2Cl2, f) solid-phase synthesis.

The UV-melting temperature experiments were performed as well to test the Se-DNA stability.
The experiments were performed using the samples (2 µM DNA duplexes) dissolved in the buffer of 50
mM NaCl, 10 mM NaH2PO4-Na2HPO4 (pH 6.5), 0.1 mM EDTA and 10 mM MgCl2. The samples were heated to 85 oC and allowed to cool down to room temperature slowly. These experiments were carried out
by Cary 300 UV-Visible Spectrophotometer with a temperature controller at a heating rate of 0.5
o

C/min.
To study the structural details of this selenium modification DNA, we were able to crystallize this

Se-DNA and solved the structure in high resolution. The self-complementary Se-DNA (5’-G-dU2’-Se-GTASe

C-AC-3’) crystallized in 1-2 weeks in 20 out of 24 buffer conditions when the Nucleic Acid Mini Screen

kit (Hampton Research, with 24 diversified crystallization buffers) was screened. The crystals grown in
buffer #5 [10% (v/v) MPD, 12 mM spermine tetra-HCl (pH 6.0), 80 mM KCl, 20 mM MgCl2] were used for
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diffraction data collection; the crystals diffracted well. X-ray diffraction data were collected at beam line
X29A in NSLS of Brookhaven National Laboratory. Two data sets were collected: one at selenium K-edge
(0.9795 Å) for SAD phasing and the other at 0.9795 Å for the molecular replacement. The data collected
for SAD phasing was used for the final refinement, and the structure of the Se-DNA was solved at 1.80 Å
resolution. The diffraction data were processed using HKL2000 and SHELXS.
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2.4.3

Enzymatic Inhibition to Methyltransferase and Endonuclease

DNA methylation is an epigenetic process to add a methyl group to the 5-position of cytosine,
and it has several effects on chromatin structure modulation, transcriptional repression and the suppression of transposable elements. DNA methyltransferase inhibitors are some nucleoside analogues
that provide novel opportunities to inhibit hypermethylation, reverse these epigenetic mutations and
provide cancer therapy. One of these compounds (5-azacytidine, Vidaza) has been approved as an antitumor agent, and others are presently in various stages of their preclinical or clinical development. Four
inhibitors, which are analogs of the nucleoside deoxycitidine, have been clinically tested: 5-azacytidine,
5-aza-2′-deoxycytidine, 5-fluoro-2’-deoxycytosine and Zebularine. The first two have demonstrated encouraging anti-leukemic activity. Since our selenium functionality generates no perturbation to the nucleic acid structure and functions, we hope that the selenium modified cytosine analogues can provide
some new DNMT inhibitors due to the special electronic and steric properties of selenium elements.
Also the unique contribution of selenium in crystallography might help to study DNMT crystal structure
and functions.
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Figure 2.4 Potential DNA methyltransferase inhibitors.
In order to study how this 5-Se-dC can inhibit methyltransferase and related endonuclease, we
chose the M.HhaI methyltransferase and Hinp1i endonuclease to manipulate, which are able to selectively recognize the GCGC sequence. M.HhaI methyltransferase can add one methyl group to each single
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strand of duplex, and Hinp1i can cleave the oligonucleotides containing GCGC sequence. The complementary sequences are designed and shown (Figure 2.5).

A

me
M.HhaI: 5'-...GCGC...-3'
3'-....CGCG...-5'
me
Hinp1I: 5'-...G↓CGC...-3'
3'-...CGC↓G...-3'

B

Oligo A:
5'-TCCATGCGCTGAC-3'
Oligo Ase: 5'-TCCATGCSeGCTGAC-3'
Oligo Ame: 5'-TCCATGCmeGCTGAC-3'
Oligo B:
3'-GGTACGCGACTGT-5'
Oligo Bse: 3'-GGTACGCSeGACTGT-5'
Oligo Bme: 3'-GGTACGCmeGACTGT-5'

Figure 2.5 A) Sequences those methyltransferase and endonuclease recognize. B) The different sequences designed and synthesized for methylation and digestion experiment. Me is the methylation sits;
arrow is the cleavage site for endonuclease; CSe is the 5-Se-dC; Cme is the 5-Me-dC.

After the solid phase synthesis and purification of these designed DNAs (same procedure as
mentioned above), the two complementary sequences were annealed to form the duplex. Both native
and modified duplexes were methylated by M.HhaI methyltransferase following New England Biolab
manufactures recommendations. After reaction, reaction samples were deactivated and precipitated to
remove the enzyme and salts. Then the samples were re-dissolved in water and analyzed by MALDI-TOF
MS. In the MS analysis, 3-Hydroxypicolinic Acid (3-HPA) was applied as matrix. 50 g/L 3-HPA was diluted
with DNA at 1:10 ratio to assist signal generation. The mass peaks in the spectrum were intergrated to
calculate the methylation reaction efficiency. In order to test endonuclease digestion effect, the same
samples were also 5'-32P labeled using T4 polynucleotide kinase (New England Biolabs) following manufactures recommendations, and treated with endonucleases Hinp1I following the manufactures recom-

63
mendations. The reaction samples were analyzed by PAGE gel electrophoresis after quenched by loading
dye. The gels were dried and exposed to film for analysis.
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2.5 Synthesis of 4, 5-Diselenium-Thymidine Nucleoside and DNA
2.5.1

Introduction

Selenium element was found in some natural nucleic acids and proteins, such as 2-selenouridine
and 5-[(methylamino)methyl]-2-selenouridine (mnm5se2U) in tRNA, and selenocysteine residue. This
selenium functionality provides both RNA and protein with many unique biochemical and biological
functions owing to its larger size and unique chemical and electronic properties. For example, the 2seleno functionality in tRNA most likely improves the translation accuracy and efficiency.
Another important property of selenium in proteins and nucleic acids is that it can serve as a
good anomalous scattering center in X-ray diffraction with a special K edge of 0.9795 Ǻ (12.6578 keV).
The anomalous scattering was caused by the resonance between beams of X-ray waves and electronic
transitions from bound atomic orbitals. By making diffraction measurements at selected wavelengths
associated with a particular resonant transition, the determination of 3-D structures can depend on solving a few anomalous scattering centers instead of each single atom. MAD (multiple wavelength anomalous dispersion) is most applied due to the advantages for accuracy in phase evaluation in that isomorphism is perfect, relative scattering strength and phase power increase with scattering angle, diffraction
data can be measured from a single crystal and algebraically exact analysis is possible. In principle, an
accessible spectral range for MAD experiments can be considered to the window from ~0.3 to ~3.0 Å in
wavelength (4 to 40 keV in energy). Either intrinsic metal centers (e.g. Fe or Zn) or introduced heavy atoms (e.g. Hg, Au or Gd) are suitable, but their instability is always a problem. Fortunately, systematic
biological incorporation of selenomethionine provides the possibility to solve protein crystal structure
by MAD. It has been proved that selenium is very effective and successful as a center for MAD phasing,
and the novel strategy has greatly revolutionized the protein X-ray crystallography field. It is estimated
that about two thirds of all new crystal structures of proteins are now determined by this strategy. Due
to the great functionality of selenium for X-ray crystallography, our lab pioneered the chemical and en-
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zymatic synthesis of selenium-derivatized nucleic acids (SeNA) for structural study since 1998. . So far,
our results suggested that this derivatization can become a better alternative to the conventional Br
derivatization in terms of stability during the exposure of crystal sample in X-ray, and comparing the limited sites of bromine modification, the selenium strategy has more site-options since there are so many
oxygen atoms available in nucleic acids and this selenium derivatization doesn’t cause significant structure perturbation when replacing oxygen atoms in nucleic acids. Currently a lot of SeNA crystal structures, including DNA and RNA, have been successfully solved in high resolution. Traditionally, we selectively replaced one oxygen atom with selenium in a single nucleotide, and this selenium functionality
was incorporated into nucleic acid. Based on a rudimentary calculation on X-ray phasing power of a selenium scatter, one selenium atom can enable phase determination for DNA or RNA up to 30 nucleotides. Therefore, for the structure determination of longer oligonucleotides, more selenium atoms’ incorporation is necessary. Instead of the single selenium modification in only one nucleotide, we decided
to synthesize some nucleoside analogue containing two selenium atoms, and in this way it can provide
more power as scattering centers.
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2.5.2

Synthesis Strategy

The synthesis (Scheme 2.6) of deoxyuridine analogue containing two selenium atoms started
from the synthetic 5’-DMTr-5-methylselenyl-deoxyuridine (1)90. To avoid the possible competition between 3’-hydroxy group and 4-position, the protection of 3’-position was performed. Considering the
fact that the introduced 4-Se functionality will be sensitive to strong acid or base environment, this 3’protection group should be able to be removed under mild conditions. Therefore, we chose the
trimethylsilyl protecting group, which can fall off during the silica gel flash column chromatography. To
introduce selenium element into 4-position, compound 2 was first activated by triisopropylbenzenesulfonyl (TIPS) group. Like the synthesis strategy in 5-Se-dC chapter, the initial attempt to isolate the
TIPS-activated 5-Se-thymidine failed due to the instability of this TIPS-activated pyrimidine derivative.
Finally, we decided to replace this TIPS group with 2-nitrophenyl group, which could improve the nucleoside stability. After isolating this 5’-DMTr-5-methylselenyl-4-(2’-nitrophenyl)-deoxyuridine (3), we did
the substitution reaction using the cyanoethylselenide as replacing reagent, to achieve compound 4. The
next step is the conversion of compound 4 to the corresponding phosphoramidite (5) in high yield. It
was found that this selenium functionality is stable under the synthetic conditions (including strong
base, fluoride treatment, I2 oxidation, and strong acid treatments) and purification. This double selenium thymidine phosphoramidite 6 was found compatible with the conditions of the solid-phase synthesis, and the stability of moiety allows us to successfully synthesize the Se-oligonucleotides using the
ultramild protecting groups. The synthesized Se-DNAs were purified and analyzed by HPLC and MS.
Syntheses strategies: after 5-methylseleno-5’-O-(4,4-dimethoxytrityl)-2’-deoxyuridine90 (624 mg,
MW 624, 1 mmol) was dissolved in acetonitrile 10 mL, 1-methylpyrrolidine (0.95 mL, 10 mmol, 10 eq.)
and trimethylsilyl chloride (3.1 mL, 3 mmol, 3 eq.) were added sequentially. The reaction mixture was
stirred for 1 hour, and all the starting material was consumed by monitoring on TLC (5% methanol/dichloromethane) to get compound 2. After completion, the reaction solution was directly trans-
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ferred to vac-line to evacuate all the solvent and base. In this way, the further purification and the potential TMS group falling off were avoided.
After drying the synthesized compound 2 for overnight, acetonitrile 10 mL was injected into reaction flask, before the diisopropylethyl amine (1.05 mL, 5 mmol, 5 eq.), triisopropylbenzenesulfonyl
chloride (905 mg, 2.5 mmol, 2.5 eq.) and p-dimethylamino pyridine (150 mg, 1 mmol, 1 eq.) were added
sequentially. The reaction mixture was stirred for 16 hours and monitored on TLC (ethyl acetate/hexane,
3:7). Because of the 4-TIPS-5-Se-thymidine is too unstable to decompose in silica gel column, we decided to do the one-pot reaction to synthesize 4-nitrophenyl substituted compound instead of isolateng 4TIPS substituted compound. Therefore, excessive 2-nitrophenol compound (1.37 g, 10 mmol, 10 eq.),
triethylamine base (0.4 mL, 3 mmol, 3 eq.) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.15 mL, 1 mmol, 1
eq.) were added drop-wise and the reaction was stirred under room temperature for 4 hours. After the
reaction was completed (monitored on TLC, 50% ethyl acetate in dichloromethane, Rf =0.65), the organic
solvent was evaporated under reduced pressure. A silica gel column was equilibrated with CH2Cl2 before
the crude product was loaded and purified on the column. The product was eluded by ethyl acetate in
CH2Cl2 (10-50%). The fractions containing the product were combined, evaporated and dried on high
vacuum overnight to yield a yellow solid 3 (588 mg, yield= 79%). 1H-NMR (400 MHz, DMSO) δ: 2.14 (s,
3H, SeCH3), 2.24-2.28 and 2.65-2.66 (2x m, 2H, H-2’), 3.42-3.44 (2x m, 2H, H-5’), 3.81 (s, 6H, 2x OMe),
4.11-4.12 (m, 1H, H-3’), 4.12-4.13 (m, 1H, H-4’), 6.16-6.19 (t, J= 5.6 Hz, 1H, H-1’), 6.85-8.16 (m, 17H,
arom-H), 8.40 (s, 1H, H-6). 13C NMR (100 MHz, DMSO) δ: 8.94 (SeCH3), 42.25 (C-2’), 55.32 (OMe), 63.49
(C-5’), 72.14 (C-3’), 87.74 (C-4’), 86.92 (C-1’), 113.34 (C-5), 125.52 (arom-C), 126.18 (arom-C), 127.02
(arom-C), 127.60 (arom-C), 128.10 (arom-C), 130.13 (arom-C), 135.27 (arom-C), 135.59 (arom-C), 145.46
(C-6), 149.13 (C-2), 154.83 (C-4). HR-MS (ESI-TOF, possitive ion mode): molecular formula, C37H37N3O9Se:
[M+Na-2H]+: 768.1447 (calc. 768.1436).
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The NaBH4 suspension (130 mg NaBH4 in 4 mL of EtOH) was injected into a flask containing di(2cyanoethyl) diselenide [(NCCH2CH2Se)2, 0.35 mL, d= 1.8 g/mL] and ethanol (8 mL) on an ice bath and under argon. After injection of the NaBH4 suspension for 30 minutes, the ice bath was removed. The yellow
color of the diselenide disappeared in approximately 15 min, giving an almost colorless solution of sodium selenide (NCCH2CH2SeNa). The solution of 3 (438 mg, 0.59 mmol) in THF (4 mL) was injected to the
solution of sodium selenide. After the selenium incorporation was completed in 15 min. (monitored on
TLC, 50% ethyl acetate in CH2Cl2, product Rf = 0.4), water (100 mL) was added to the reaction flask. The
solution was adjusted to pH 7-8 using CH3COOH (10%), and was then extracted with ethyl acetate (3 x
100 mL). The organic phases were combined, washed with NaCl (sat., 100 mL), dried over MgSO4 (s) for
30 min, and evaporated under reduced pressure. Deprotecting solution (5 mL, 10% triethylamine in
methanol) was added to the crude product, and the reaction was stirred for 4 hours to completely remove the 3’-TMS group. After evaporating the deprotecting solution, the crude product was then dissolved in methylene chloride (5 mL) and purified on a silica gel column. The column was eluded with a
gradient of ethyl acetate/methylene chloride (10-50%). After solvent evaporation and dry on high vacuum, the pure compound (4) was obtained as a light yellow foamy product (332 mg, 75% yield). 1H-NMR
(400 MHz, DMSO) δ: 2.04 (s, 3H, SeCH3), 2.30-2.31 and 2.95-2.97 (2x m, 2H, H-2’), 2.97-2.99 (t, 2H,
SeCH2CH2CN), 3.25-3.28 (t, 2H, SeCH2CH2CN), 3.40-3.41 (2x m, 2H, H-5’), 3.80 (s, 6H, 2x OMe), 4.09-4.16
(m, 1H, H-3’), 4.51-4.52 (m, 1H, H-4’), 6.17-6.20 (t, J= 6.4 Hz, 1H, H-1’), 6.80-7.40 (m, 13H, arom-H), 8.19
(s, 1H, H-6).

13

C NMR (100 MHz, DMSO) δ: 10.69 (SeCH3), 14.21 (SeCH2CH2CN), 22.11

(SeCH2CH2CN),42.18 (C-2’), 55.28 (OMe), 63.24 (C-5’), 72.41 (C-3’), 86.85 (C-4’), 87.59 (C-1’), 113.32
(arom-C), 119.03 (C-5), 127.08 (arom-C), 128.03 (arom-C), 130.07 (arom-C), 135.38 (CN), 145.41 (C-6),
158.69 (C-2), 182.66 (C-4).HR-MS (ESI-TOF, negative ion mode): molecular formula, C34H37N3O6Se2:
[M+Na-2H]-: 764.0764 (calc. 764.0754).

69
4-cyanoethylselenyl-5-methylseleno -5’-O-(4,4-dimethoxytrityl)-2’-deoxyuridine (4, 200 mg, MW
741.2, 0.27 mmol) was placed in a 25 mL round flask and dried on high vacuum. Dry CH2Cl2 3 mL, N,Ndiisopropyl-ethylamine

0.06

mL

(0.4

mmol,

1.5

eq.)

and

2-cyanoethyl

N,N-diisopropyl

chlorophosphoramidite 80 mg (0.4 mmol, 1.5 eq.) were then added sequentially. The reaction mixture
was stirred at room temperature for 2 hours, and the reaction completion was indicated by TLC (4%
MeOH/CH2Cl2, Rf=0.3 and 0.32, two diastereomers). The reaction was then quenched with NaHCO3 (sat.)
and extracted with CH2Cl2 three times, and dried over anhydrous MgSO4, followed by filtration and solvent evaporation. The crude product was re-dissolved in CH2Cl2 (3 mL) and this solution was added
dropwise to pentane (200 mL) under vigorous stirring to yield yellow precipitate. The pentane solution
was decanted carefully (sometimes filtration was necessary) and the crude product was loaded into a
silica gel column that was equilibrated with CH2Cl2 containing 1% triethylamine. The product was eluted
with an increasing stepwise gradient of MeOH/CH2Cl2 in the presence of 1% triethylamine (1-5%). The
fractions containing target compound were combined evaporated under reduced pressure to afford a
yellow solid (216 mg, yield= 85%).
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Scheme 2.6 Reaction scheme of synthesis of 4, 5-seleno-derivatized thymidine DNA. a) trimethylsilyl
chloride, 1-methylpyrrolidine, acetonitrile; b) triisopropylbenzenesulfonyl chloride, diisopropylethyl
amine, dimethylammonium pyridine, acetonitrile; c) 4-nitrophenol, triethyl amine, 1,8Diazabicycloundec-7-ene, acetonitrile; d) di-2-cyanoethyl diselenide, NaBH4, ethanol, THF; e) 2cyanoethyl N,N-diisopropylchlorophosphoramidite, N,N-diisopropylethyl amine, dichloromethane; f)
solid-phase synthesis.
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2.6 Facilitation of Selenium Modification on Nucleic Acid Crystallization
2.6.1

Introduction

Beside the advantage of selenium functionality in solving phase problem in crystallography, it
has been discovered accidentally that selenium modification has dramatic facilitation to the growth of
oligonucleotide crystal. It was found that the modifications at the 2’ position of deoxyribouridine could
facilitate the crystal growth of a DNA-8mer model 5’- GUGTACAC-3’. Compared with other groups such
as SMe, -OMe, -OH, and -F, methylseleno group has much stronger effect to make the crystals growth
happen in minutes. The real-time monitor of crystallization and comparison of different derivatizations
were performed as well, and to obtain the single crystal with a fixed shape is possible by modifying DNA
sample. It was proposed that this selenium modification at 2’ position of the ribose could lock the sugar
pucker into 2’-exo form which provides a perfect scafford for the next molecular packing, while the other modifications generates more dynamic equilibrium for the ribose between the 2’-exo and 2’-endo
form. The dynamic study of molecular packing was done for the first time, although the mechanism for
the nucleation process is unclear yet. Accidently, in the structural study of DNA containing 2-Seleniummodification, we also observed the phenomenon that Se-derivatized oligonucleotides can crystallize
much faster than native one. Compared with the selenium modification in sugar, this nucleobase modification must have different mechanism to facilitate crystallization. It encourages us to do systematic
experiments to explore the reason that selenium functionality can affect the crystal growth rate.
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2.6.2

Crystallization Screening

The 2-seleno-thymine phosphoramidite was synthesized using the same strategy discussed in
chapter 2. The oligonucleotide 5’-GTGT2SeACAC-3’ was synthesized and purified by the standard DNA
synthesis procedure. In the DNA sample, the incorporation of 2’-Se-thymidine was avoided to reduce
the impact of known 2’-Se-functionality on crystallization facilitation. The corresponding native DNA 5’GTGTACAC-3’ was also synthesized and purified. The Hampton research nucleic acid mini-screen buffers
were used to find the best conditions and compare two different samples. The native buffer condition
without precipitant was also used.

73
3.

RESULTS AND DISCUSSION
3.1 Synthesis of 5-Selenium-Thymidine DNA for Structural and Enzymatic Study
5-Se-thymidine (5-Se-T) phosphoramidite 5 was found compatible with the conditions of the sol-

id-phase synthesis, including the coupling reaction, acetylation capping, I2 oxidation, and trichloroacetic
acid and concentrated ammonia treatments. All the 5-Se-T-modified oligonucleotides were synthesized
chemically on a 1.0 µmol scale using an ABI392 DNA/RNA Synthesizer. The concentration of the Senucleoside phosphoramidites was identical to that of the conventional phosphoramidites (0.1 M in acetonitrile). Coupling was carried out using a 1H-tetrazole solution in aectonitrile. The coupling time was
25s. Syntheses were performed on control pore glass (CPG-500) immobilized with the appropriate nucleoside through a succinate linker (Glen Research). All the oligonucleotides were prepared with DMTron. After synthesis, the DNA oligonucleotides were cleaved from the solid support and fully deprotected
by aqueous ammonia (conc.) treatment for 14 h at 55 oC. The 5’-DMTr deprotection of DNA oligonucleotides was performed in a 3% trichloroacetic acid solution (from 10% w/w, 0.9 M in water) for 1.5 min,
followed by neutralization to pH 7.0 with a freshly made aqueous solution of triethylamine (1.1M) and
petroleum ether extraction to remove DMTr-OH. The stability of the 5-Se-T moiety allows us to successfully synthesize the Se-oligonucleotides using the normal phosphoramidites. The DNA oligonucleotides
were analyzed and purified by reverse-phase high performance liquid chromatography (RP-HPLC) both
DMTr-on and DMTr-off. Purification was carried out using a 21.2 x 250 mm Zorbax, RX-C8 column at a
flow rate of 6 ml/min. Buffer A consisted of 20 mM triethylammonium acetate (TEAAc, pH 7.4, RNasefree water), while buffer B contained 50% aqueous acetonitrile and 50 mM TEAAc, pH 7.1. Similarly,
analysis was performed on a Zorbax SB-C18 column (4.6 x 250 mm) at a flow rate of 1.0 ml/min using
the same buffer system. The DMTr-on oligonucleotides were eluted with up to 90% buffer B in 25 min in
a linear gradient, while the DMTr-off oligonucleotides were eluted with up to 40% of buffer B in a linear
gradient in the same period of time. The collected fractions were lyophilized; the purified com-pounds
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were redissolved in RNase-free water. The pH was adjusted to 7.0 after the final purification of the Seoligonucleotides without the DMTr group. A typical HPLC profile of the synthesized crude Se-DNAs is
shown in Figure 3.1, which is virtually identical to that of the corresponding native DNA. We determined
that the coupling yield of the 5-Se-T phosphoramidite was over 99%. The synthesized Se-DNAs were purified and analyzed by HPLC and MS (Table 3.1 and Figure 3.2). Our UV-melting data (Table 3.2) show
that the melting temperature differences of the native and Se-modified DNA duplexes are small (less
than 1.0 °C per modification), whereas the melting temperature of the S-modified (5-MeS-T) DNA duplex
is the lowest stable (approximately 3 °C lower than that of the native). Lower stability of the 5-S-T DNA
duplex is probably due to the shorter S-C bond length compared with the Se-C one, which may better
facilitate the 5-methyl/phosphate backbone interaction. In most cases that we examined (Table 3.2), the
native duplexes are slightly more stable than the corresponding Se duplexes. Our results suggest that
the insertion of a Se atom at the exo-5-position of thymidine does not cause significant structure perturbation. It is counterintuitive that the larger selenium atom causes less destabilization than smaller
sulfur atom, although both disrupt the 5-CH3/π interaction with the preceding 5′- nucleobase. It appears
that the larger Se-linker allows the methyl/phosphate stabilizing interaction.

Figure 3.1 HPLC analysis of crude 5′-DMTr-TT-5-SeT-T-3′ (15.3 min).
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Table 3.1 MALDI-TOF MS Data of the 5-Se-T DNAs.

Figure 3.2 HPLC analysis of the native and modified DNAs. The blue profile: the native DNA (5’CTTCTTGTCCG-3’, retention time= 11.8 min); the red profile: the S-modified DNA (5’-CTTCT5-STGTCCG-3’,
retention time= 12.4 min); the green profile: the Se-modified DNA (5’-CTTCT5-SeTGTCCG-3’, retention
time= 13.2 min). A linear gradient was run from Buffer B 0% to 35% in 15 minutes.

Table 3.2 UV Melting Temperatures of the 5-Se-T DNAs
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Similar to other Se-derivatized nucleic acids (SeNA), these novel 5-Se-T DNAs are also stable. The
crystal growth of the self-complementary Se-DNA (5′-G-dU2′-Se-G-5-SeTACAC- 3′)2 was successfully facilitated by the utilization of 2′-MeSe-dU.6c Superimposition of the determined Se-DNA crystal structure
(1.80 Å) over the corresponding native in the same tetragonal space group reveals that these two structures are virtually identical (Figure 3.3), which is consistent with our UV-melting study. Moreover, we
observed that the 5-Se-T and A form a base pair as well as the native T-A pair (Figure 3.3, B and C). The
lengths of these two hydrogen bonds of the 5-SeT-A are 2.79 and 2.76 Å.

Figure 3.3 Global and local structures of the 5-Se-T-DNA [(5′-GdU2′-Se-G-5-SeT-ACAC-3′)2]. (A) Duplex structure of the modified DNA (3BM0, in cyan) is superimposed over the native (1DNS, in pink). (B) The experimental electron density map of the 5-SeT4:A5 base pair and CH3···O--PO3 hydrogen-bond formation. (C) The superimposition of the Se-modified (in cyan) and native (in pink) local 5-SeT4:A5 structures.

We also closely examined the geometry of the 5-CH3 moiety extended by the selenium insertion
(Figures 3.4). Excitingly, the 5-methyl group clearly points to the 5′- phosphate backbone, and strong
experimental electron density exists between them, although the major groove is wide open and available to accommodate the 5-Me-Se moiety. As a typical hydrogen-bond length (X-H···Y) is between
2.8 and 3.2 Å, the distance (2.93 Å) between the carbon of the 5-methyl group and the pro-Sp oxygen of
the 5′-phosphate (Figure 3.4C) indicates formation of a methyl/phosphate hydrogen bond (CH3···O-
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-PO3). In addition, our observation on the CH3···O--PO3 interaction is consistent with the interactions between C-H and other electron donors, such as C-H···O=C hydrogen bond in proteins [bond
length (3.14 Å) and angle (149°)] and C-H···O=C interaction in uracil crystal [hydrogen-bond length
(3.21 Å) and angle (161°)]. The angle of the C-H···O in the 5-Me-Se-T DNA structure is 144°, which
further supports the C-H···O hydrogen-bond formation. The CH3 rotation about the single bond
between the Se and C allows the three hydrogen atoms to have equal opportunity to interact with the
pro-Sp oxygen, which strengthens the C-H···O--PO3 interaction.

Figure 3.4 Global and local structures of the 5-Se-T-DNA [(5′-GdU2′-Se-G-5-SeT-ACAC-3′)2]. (A) The duplex
structure of the modified DNA (3BM0, in cyan). (B) Single-strand structure. (C) Methyl group and pro-Spoxygen in the local structure.

Furthermore, in our structural comparison with the native structure, we found that the Se insertion disrupts the weak 5-CH3/π interaction in the native structure, which results in slight reduction of the
duplex stability. On the other hand, the intramolecular hydrogen bond slightly stabilizes the intermolecular interaction (the duplex stability) due to the possible pre-organization (slight entropy decrease of the
Se modified single strand). Therefore, our UV-melting observation on the slight destabilization or stabili-
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zation of the Se-DNA duplexes (1.0 °C per modification) is consistent with these two conflicting interactions, with the sequence and modification dependences, in the presence of the Se modification and the
C-H···O--PO3 hydrogen bond. Furthermore, lower stability of the S-DNA duplex is consistent with
this C-H···O--PO3 interaction in the Se-DNA duplex. As shown in Figure 3.4, negatively charged oxide orientates the 5-methyl group toward DNA backbone, instead of the major groove, for better interaction. Thus, our results indicate the first observation of the C-H···O--PO3 hydrogen bond.
In conclusion, we have discovered a novel C-H···O hydrogen bond (or CH3···O--PO3 interaction) via the biophysical and structural studies and the synthesis of the 5-Se-thymidine and the 5Se-derivatized DNAs. Our experimental results have revealed that the Se-modification does not cause
significant perturbation of the native DNA structure. This unique CH3···O--PO3 interaction can be
used to advantage in designing inhibitors for the backbone digestion. Our research results have suggested a new research direction to design and develop nuclease-resistant DNAs and RNAs functioning as antisense DNAs, siRNAs, or microRNAs. Moreover, our exciting discovery of the C-H···phosphate hydrogen bond may provide new insight into atomic mechanisms of phosphorylation and
dephosphorylation, which are common strategies in cellular signal transduction regulations. Furthermore, this selenium-derivatization has great potential in the determination of nucleic acid crystal structures via multiwavelength anomalous dispersion (MAD) or single-wavelength anomalous (SAD) phasing.
The same strategy was applied to accomplish the syntheses of 5-SMe-T phosphoramidite and 5SePh-T phosphoramidite.
The solid-phase syntheses of oligonucleotides containing 5-chalcogen-T modifications were performed under regular conditions. The detailed procedure was the same as before. The preparation, purification and analyses of these synthetic oligonucleotides were in same procedure as 5-Se-T containing
DNA. The HPLC spectra showed the DNAs were pure. The MS spectra showed the chalcogen elements
were incorporated into DNAs. The MS analytical data was shown in Table 3.3.
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Table 3.3 MALDI-TOF MS data of the 5-chalcogen-T DNAs.
entry
1

Se-oligonucleotide
5’-GdU2’-SeG-CH3SeT-ACAC-3’
C78H99N30O46P7Se2

measured (calcd.) m/z
+
[M+H] : 2568.6 (2569.0)

2

5’-ATGG-CH3SeT-GCTC-3’
C88H112N32O54P8Se

[M]+: 2808.7 (2808.4)

3

5’-CTCCCA-CH3SeT-CC-3’
C84H111N27O53P8Se

[M+H] : 2674.6 (2674.5)

4

5’-CTTCT-CH3SeT-GTCCG-3’
C106H138N32O69P10Se

[M] : 3353.3 (3352.6)

5

5’-GdU2’-SeG-CH3ST-ACAC-3’
C78H99N30O46P7SSe

[M] : 2520.6 (2521.1)

6

5’-ATGG-CH3ST-GCTC-3’
C88H112N32O54P8S

[M] : 2761.7 (2760.8)

7

5’-CTCCCA-CH3ST-CC-3’
C84H111N27O53P8S

[M] : 2626.6 (2626.7)

8

5’-CTTCT-CH3ST-GTCCG-3’
C106H138N32O69P10S

[M] : 3306.3 (3305.8)

9

5’-GdU2’-SeG-CH3OT-ACAC-3’
C78H99N30O47P7Se

[M+H] : 2505.6 (2505.8)

10

5’-ATGG-CH3OT-GCTC-3’
C88H112N32O55P8

[M+Na] : 2869.7 (2871.5)

11

5’-CTCCCA-CH3OT-CC-3’
C84H111N27O54P8

[M+H] : 2611.6 (2611.0)

12

5’-CTTCT-CH3OT-GTCCG-3’
C106H138N32O70P10

[M+H] : 3291.3 (3290.9)

13

5’-GdU2’-SeG-PhSeT-ACAC-3’
C83H101N30O46P7Se2

[M]+: 2629.6 (2627.9)

14

5’-ATGG-PhSeT-GCTC-3’
C93H114N32O54P8Se

[M+H] : 2872.7 (2873.6)

15

5’-CTCCCA-PhSeT-CC-3’
C89H113N27O53P8Se

[M+H] : 2736.6 (2736.7)

16

5’-CTTCT-PhSeT-GTCCG-3’
C111H140N32O69P10Se

[M] : 3415.3 (3415.9)

+

+

+

+

+

+

+

+

+

+

+

+

+

Similar with 5-Se-T DNAs, the UV-melting temperatures were measured to examine the impact
of the modified incorporation on the thermodynamic stability of DNA duplexes. The 5-position of thymi-
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dine has been extensively modified by selenium, which shows duplex formation without significant perturbation. Similarly, the other chalcogen modifications, such as 5-CH3S, 5- CH3O, and 5-PhSe, are not expected to cause significant lost in duplex thermostability. Melting temperatures of modified DNAs are
summarized in table 3.4. Our experimental results indicated that the CH3Se-, CH3S- and CH3O- derivatized
DNAs had almost the same thermostability as native DNAs. That is probably because the 5-chalcogenmodification was tolerated by the duplex major groove, and the electron delocalization ability of
chalcogen elements contributed partially to the stacking interaction. However, the 5-PhSe-modified
DNAs showed slightly lower melting temperatures than native ones, possibly due to the steric effect of
larger phenyl group. The typical melting curves are shown in supporting information.

Table 3.4 UV melting temperatures of the 5-chalcogen-T DNAs.
entry

oligonucleotides system

base pair

1

5’-ATGGXGCTC-3’
5’-GAGCACCAT-3’
(X=T, or 5CH3SeT or
5CH3ST or 5CH3OT or
5PhSeT)

T/A
5CH3SeT/A
5CH3ST/A
5CH3OT/A
5PhSeT/A
T/A
5CH3SeT/A
5CH3ST/A
5CH3OT/A
5PhSeT/A
T/A
5CH3SeT/A
5CH3ST/A
5CH3OT/A
5PhSeT/A

2

3

5’-CTCCCAXCC-3’
5’-GGATGGGAG-3’
(X=T, or 5CH3SeT or
5CH3ST or 5CH3OT or
5PhSeT)
5’-CTTCTXGTCCG-3’
5’-CGGACAAGAAG-3’
(X=T, or 5CH3SeT or
5CH3ST or 5CH3OT or
5PhSeT)

melting temp
o
( C, ± 1.0)
40.3
39.3
39.8
40.1
38.5
36.5
36.3
36.8
36.9
36.2
44.9
43.9
43.2
44.3
42.7

To test the enzymatic inhibition of these 5-chalcogen-midified T to the nuclease, after the solid
phase synthesis and purification of these designed DNAs (same procedure as mentioned above), both
native and modified oligonucleotides were 5'-32P labeled using T4 polynucleotide kinase (New England
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Biolabs) following manufactures recommendations. The γ-32P ATP was removed before the single strand
DNA oligonucleotide was annealed with the complementary strand. The double stranded DNAs were
treated with endonucleases AseI and SalI, and exonuclease III following the manufactures recommendations. The reaction samples were analyzed by PAGE gel electrophoresis after quenched by loading dye.
The gels were dried and exposed to film for analysis. Figure 3.5 shows the different chalcogen modifications on DNA had different impact on AseI endonuclease’s hydrolysis. After digestion overnight, over 95%
native DNA1 was cleaved. When the oligonucleotide was modified with 5-CH3Se, the DNAs showed extremely strong inhibition to the endonuclease. No cleavage happened on DNA2, DNA3 and DNA4, and
only 35% was digested on DNA5 (figure 3.5, A). This result accorded with our expectation, because the
modifications on DNA2, 3 and 4 are relatively close to the cleavage site. When the modification was altered to other elements, like O and S, the inhibition efficiency was changed as well (figure 3.5, B and C).
When the modification was 5-CH3O, only DNA2 and DNA3 showed resistance to a weak extent, DNA4
and DNA5 had no resistance at all (figure 3.5, B). The 5-CH3S modification had the similar situation. The
only distinction was that DNA2 and DNA3 showed stronger resistance than 5-CH3O modification (figure
3.5, C). What surprised us was that the 5-PhSe modification, though it had the selenium element and
bulky phenyl group, possessed weaker inhibition than 5-CH3Se group (figure 3.5, D). Only the 5-PhSe-T
DNA2 showed complete inhibition to the endonuclease, and all DNA3, DNA4 and DNA5 showed weaker
resistance. Considering the fact that the only difference was the external alky group, we speculated that
the small methyl group was easier to interfere phosphodiester bond cleavage by some methyl-phosphate
interaction. This can be grounded from the crystal structures we published before90. We got similar conclusion from the experiment results of SalI endonuclease and exonuclease III.
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(A)

(B)

(C)

(D)

Figure 3.5 Resistance study of 5-chalcogen-T DNAs to endonuclease AseI. A) X=5-CH3Se-T-DNA; B) X=5CH3O-T-DNA; C) X=5-CH3S-T-DNA; D) X=5-PhSe-T-DNA.
We also performed the time-course kinetic experiment to study the inhibition effect of 5chalcogen-T modified DNAs to the nuclease. The same operation was done as mentioned before in different time scales. Figure 3.6 shows the DNA5, which has different modifications, has variable impact on
the inhibition. After 2 hours’ digestion, native DNA was completely hydrolyzed to small fragments, and
the reaction was fast (figure 3.6, A). When the DNA was derivatized with CH3Se group, even though it
was 5 nucleotides far way from 3’- end, the exonuclease was 100% inhibited (figure 3.6, D). However,
when the modifications were changed to 5-CH3O and 5-CH3S, the DNAs behaved almost the same as native one, and they were completely digested. Similar as before, 5-PhSe didn’t show as strong inhibition
as 5-CH3Se modification.
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A)

B)

C)

D)

E)

Figure 3.6 Comparison of inhibition of different modifications in DNA5 to exonuclease III. (A) native DNA;
(B) 5-CH3O-T DNA; (C) 5-CH3S-T DNA; (D) 5-CH3Se-T DNA; (E) 5-PhSe-T DNA.

Figure 3.7 shows the time-course experiment on 5-CH3Se-T DNAs’ inhibition to AseI. As mentioned above, DNA2, DNA3 and DNA4 had complete resistance to digestion, and DNA5’s digestion reaction rate was similar as native DNA. All different types of modified DNAs were tested under AseI, SalI endonuclease and exonuclease III. The relative inhibition efficiency are summarized and listed in table 3.5.
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A)

B)

C)

D)

E)

F)

Figure 3.7 Comparison of different 5-CH3Se-T DNAs’ inhibition to endonuclease AseI. (A) native DNA; (B)
DNA2; (C) DNA3; (D) DNA4; (E) DNA5; (F) digestion curve.

Table 3.5 Relative inhibition efficiency of different modified DNA under different nuclease environment.
(inhibiton
efficiency)

DNA
1

DNA2

DNA3

DNA4

DNA5

OMeSMeSeMeSePh OMeSMeSeMeSePh OMeSMeSeMeSePh OMeSMeSeMeSePh

AseI

1.0 2.0 140 200 200 1.0 20

59

28 1.0 3.4 59

3.7 1.0 1.1 1.1 1.1

SalI

1.0 1.0 1.0 2.5 1.7 1.0 1.5 12

2.0 1.3 1.5 83

2.0 2.0 59

Exonuclease III

91

2.0

1.0 1.0 1.0 1.0 1.0 1.0 1.1 1.1 1.0 1.0 1.1 1.2 1.1 1.2 1.2 10

2.0

Overall, the derivatization of DNA with chalcogen elements, especially selenium, can give us a
new strategy to inhibit the nuclease. By searching the structure of restriction endonuclease and
exonuclease III, the water molecules, metal cation and the amino acid residues around the cleavage site
are significant to the mechanism. Some negatively charged residues, like Aspartate and Glutamate, can
deprotonate water molecules, and then the negative hydroxyl groups can attack the phosphates as nu-
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cleophiles. We conclude that after the introduction of an extra chalcogen atom into the 5- position of
thymidine, the structure of oligonucleotide is changed slightly compared with native one. Because of the
chalcogen atoms, this chalcogen-methyl groups at 5-position will have steric hindrance with some residue, which can make the protein structure shift. After this effect the negative residues cannot interact
with water molecules, so cleavage is inhibited. Moreover, selenium element has the larger radius than
oxygen and sulfur, causing that selenium modified DNA has the strongest resistance. Meanwhile, the introduction of 5-CH3Se group can cause the methyl group point to the phosphate. If this happens, this
selenomethyl can either kick out the water molecules around the cleavage site, or form some interaction
with phosphate group. Therefore the nucleophilic water molecule in the reaction is repelled and stability
of DNA is improved, even higher than 5-PhSe modification.
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3.2 Synthesis of 2-Selenium-Thymidine DNA and Improved Base Fidelity
All the DNA oligonucleotides were chemically synthesized in a 1.0 μmol scale using an ABI392 or
ABI3400 DNA/RNA Synthesizer. The ultra-mild nucleoside phosphoramidite reagents were used in this
work (Glen Research). The concentration of the 2-Se-T phosphoramidite was identical to that of the
conventional ones (0.1 M in acetonitrile). Coupling was carried out using a 5-(benzylmercapto)-1Htetrazole (5-BMT) solution (0.25 M) in acetonitrile. The coupling time was 25 seconds for both native
and modified samples. 3% trichloroacetic acid in methylene chloride was used for the 5’-detritylation.
Synthesis were performed on control pore glass (CPG-500) immobilized with the appropriate nucleoside
through a succinate linker. All the oligonucleotides were prepared with DMTr-on form. After synthesis,
the DNA oligonucleotides were cleaved from the solid support and fully deprotected by the treatment of
0.05 M K2CO3 solution in methanol for 8 hr at room temperature. The 5’-DMTr deprotection was performed in a 3% trichloroacetic acid solution for 2 min, followed by neutralization to pH 7.0 with a freshly
made aqueous solution of triethylamine (1.1 M) and extraction by petroleum ether to remove DMTr-OH.
The DNA oligonucleotides were analyzed and purified by reversed-phase high performance liquid chromatography (RP-HPLC) both DMTr-on and DMTr-off, following the same procedure we used in
previous work. The MS results are shown in Table 3.6.

Table 3.6 MS values of the 2-Se-T-containing DNAs.
Entry

Oligonucleotide

Molecular Formula

Isotopic Mass

Measured (calc.) m/z

1

T TTT

C40H35N8O25P3Se

1218.2

[M+H ] : 1219.2 (1219.2)

2

5'-CTCCCA TCC-3'

C84H103N27O52P8Se

2657.6

[M+H ] : 2658.5 (2658.6)

3

5'-ATGG TGCTC-3'

Se

C88H104N32O53P8Se

2793.8

[M+H ] : 2794.2 (2794.8)

4

5'-CTTCT TGTCCG-3'

C106H128N32O68P10Se

3338.1

[M] : 3338.3 (3338.1)

5

5’-GdU2’SeMeG TACAC-3’

C78H99N30O45P7Se2

2552.3

[M-H ] : 2551.3 (2551.3)

Se

Se

Se

Se

+ +

+ +

+ +

+

+ -
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Our UV-denaturation studies showed that the melting temperatures of the native and Semodified DNA duplexes (Table 1 and S2) are almost the same (approximately 0.4 oC difference), suggesting that the oxygen substitution with selenium at the 2-position of thymidine does not cause significant
perturbation. The melting temperature decrease of the SeT/T mismatched duplex (Tm= 10.7 oC) by comparing with the matched native duplex is very similar to that of the T/T mismatched duplex (Tm= 11.7 oC),
suggesting the same level of the T/T mismatch discrimination. Moreover, the Tm decrease of the SeT/G
wobble-paired duplex (Tm= 13.7 oC) is much more than that of the native T/G wobble-paired duplex (Tm=
7.0 oC), suggesting a stronger discrimination against the T/G wobble pairing after the 2-Se incorporation
(Table 3.7). Interestingly, the Tm decrease of the SeT/C-mismatched duplex (Tm= 18.7 oC) is also much
higher than that of the native T/C-mismatched duplex (Tm= 14.6 oC), suggesting a stronger selectivity
against the T/C mismatch after the 2-selenium substitution. It appears that the 2-Se-modification of
thymidine significantly increases selectivity against T/G wobble and T/C mismatches, while retaining the
same level of strong discrimination against T/T mismatched pair and the same high fidelity of the native
T/A matched base pair. Results of thermal dynamic calculation11 (Table 3.7 and 3.8) are consistent with
the UV-melting studies.
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Table 3.7 Melting temperatures of native and SeT-DNA duplexes A.
Entry

Sequences

o

o

Pairs

Tm ( C)

Tm ( C)

T/A

42.6 + 0.5

−

I: 5’-CTTCTTGTCCG3’
1
3’-GAAGAACAGGC-5’
2

I+3’-GAAGATCAGGC-5’

T/T

30.9 + 0.5

-11.7

3

I+3’-GAAGAGCAGGC -5’

T/G

35.6 + 0.5

-7.0

4

I+3’-GAAGACCAGGC -5’

T/C

28.0 + 0.5

-14.6

42.2 + 0.5

-0.4

T/T

31.9 + 0.5

-10.7

T/G

28.9 + 0.5

-13.7

23.9 + 0.5

-18.7

Se

II: 5’-CTTCT TGTCCG-3’
5

Se

T/A

3’- GAAGAACAGGC -5’
6

II + 3’- GAAGATCAGGC-5’

Se

7

II + 3’-GAAGAGCAGGC-5’

Se

8

II + 3’-GAAGACCAGGC-5’

Se

T/C

Table 3.8 Melting temperatures of native and SeT-DNA duplexes B.
Entry

Sequences & Mismatches

Pairing

o

Tm ( C)

o

( C)
III: 5’-ATGGTGCTC-3’
1

T/A

37.0 + 0.5

−

3’-TACCACGAG-5’
2

III + 3’-TACCTCGAG-5’

T/T

21.3 + 0.5

-15.7

3

III + 3’-TACCGCGAG-5’

T/G

32.0 + 0.4

-5.0

4

III + 3’-TACCCCGAG-5’

T/C

18.0 + 0.3

-19.0

36.1 + 0.7

-0.9

T/T

21.6 + 0.7

-15.4

T/G

23.3 + 0.8

-13.7

12.9 + 0.8

-24.1

Se

IV: 5’-ATGG TGCTC-3’
5

Se

T/A

3’-TACC ACGAG-5’
6

IV + 3’-TACCTCGAG-5’

Se

7

IV + 3’-TACCGCGAG-5’

Se

8

IV + 3’-TACCCCGAG-5’

Se

T/C
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Furthermore, this increase of the base pair specificity is consistent with our crystal structure
study. We have solved the X-ray crystal structure of the Se-DNA (5'-G-dU2'-Se-G-SeT-ACAC-3')2 at the
atomic resolution (Figure 3.8), via the crystallization facilitation using the 2’-Se-dU moiety33,52. Superimposition of the determined Se-DNA crystal structure (1.58 Å) over the corresponding native in the same
tetragonal space group13 reveals that these two structures are very similar (Figure 3.8C). Moreover, we
found that the SeT/A base pair is virtually identical to the native T/A pair (Figure 3.8A & 3.8B). As expected, the large selenium atom fits well in the structure, since the 2-exo-position of T is not involved in
the hydrogen bond formation with A. Furthermore, our biophysical and structural studies suggest that
the bulky 2-Se atom (a weak hydrogen-bond acceptor) may discourage the wobble pairing by both the
steric hindrance and the electronic effect: the weaker hydrogen-bonding ability of the 2-Se atom comparing to the 2-O atom in the native wobble pair. The bulky 2-Se atom does not interact with the paring
A and thus causes no disruption on the T/A pairing, which is consistent with our UV-melting study.
Therefore, the 2-Se atom bulkiness and electronic effect are probably the main factors responsible for
the discrimination against formation of the wobble SeT/G base pair, which is in a good agreement with
our UV-melting and structural results on the native and Se-modified T/G wobble pairs.
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Figure 3.8 Global and local structures of the 2-Se-T-DNA [(5’-GdU2’-Se-G-SeT-ACAC-3’)2], with a resolution
of 1.58 Å. (A) The superimposed comparison of the local SeT4/A5 (in green) and native T4/A5 (in cyan)
base pairs. (B) The experimental electron density map of the SeT4/A5 base pair with σ=1.0. (C) The superimposed comparison of the Se-DNA duplex (3HGD, in green) with its native counterpart (1D78, in cyan).
The red balls represent the selenium atoms.

In summary, we have developed the novel chemistry to first synthesize the 2-Se-derivatized
thymidine, 2-Se-T phosphoramidite, and 2-Se-T DNAs. Our biophysical studies on the 2-Se-DNAs indicate
that the perfectly-matched Se-DNA duplexes have almost the same stability as the native ones. Interestingly, the 2-Se-substitution largely increases specificity of the base pair recognition by further discouraging the T/G wobble and T/C base-pairs, providing a unique chemical strategy to further enhance basepairing fidelity. Consistently, our crystal structure study further reveals that the selenium-atomic substitution does not significantly alter the native T/A base pairing and overall duplex structure. Our experimental results indicate that this 2-Se-substitution facilitates higher specificity of the thymidine pairing
with the natural nucleobases. Moreover, this 2-Se-derivatized thymidine provides a useful tool in
derivatization and phasing for X-ray crystal structure studies of nucleic acids and their protein complexes. The Se-atom-specific probing will open new research opportunities for further investigating base-pair
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recognition and high fidelity of DNA polymerase replication, RNA polymerase transcription, and mRNA
translation.
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3.3 Synthesis of 5’-Selenium-Thymidine DNA and Convenient Fluorescence Labeling
The 5’-Se-modified oligonucleotide was synthesized chemically on a 0.2 μmol scale using an
ABI392 DNA/RNA Synthesizer. The concentration of the Se derivatized phosphoramidite was identical to
that of the conventional phosphoramidites (0.1 M in acetonitrile). Coupling was carried out using 5-BTT
solution (0.25 M) in aectonitrile. The coupling time was 25 s. Synthesis was performed on control pore
glass (CPG-500) immobilized with the appropriate nucleoside through a succinate linker (Glen Research).
Since the 5’ end was the 5’-(2-cyanoethyl)seleno thymidine, there was no DMTr group in the oligonucleotides. The HPLC and MS profiles are shown in 3.10 and 3.11, which are corresponding to the quality
and characterization of synthesized oligonucleotide containing 5’-Se-thymidine.

Figure 3.9 HPLC analysis of 5’-Se-T containing DNA (5’-dSeTGCGTAATACGACTCACTATAG-3’). Sample was
eluted with a linear gradient from buffer A (20 mM triethylammonium acetate, pH 7.1) to 60% buffer B
(50% acetonitrile, 20 mM triethylammonium acetate, pH 7.1) in 20 min. Retention time= 12.3 min.
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Figure 3.10 MALDI-TOF MS spectrum of 5’-Selenium 22mer DNA (5’-dSeTGCGTAATACGACTCACTATAG3’). Its molecular formula: C215H271N82O128P21Se; [M]+: 6775 (calc. 6779).
The procedure of fluorescent dye labeling is mentioned above. The HPLC purification was performed using a 21.2 x 250 mm Zorbax, RX-C18 column at a flow rate of 6 ml/min. Buffer A consisted of
50 mM triethylammonium acetate (TEAAc, pH 7.1, RNase-free water), while buffer B contained 50%
aqueous acetonitrile and 50 mM TEAAc, pH 7.1. This fluorescein labeled oligonucleotide was eluted with
up to 48% of buffer B in a linear gradient in 25 min. The collected fractions were lyophilized and redissolved in RNase-free water. HPLC analysis was performed on a 4.6 x 250 mm Zorbax SB-C18 column at a
flow rate of 1.0 ml/min. Buffer A and B were the same as buffers used in purification. This fluorescein
labeled oligonucleotide was eluted with up to 48% buffer B in 16 min in a linear gradient. The HPLC
spectrum in 3.12 shows the efficiency of dye labeling after the removal of the surplus dye compound, in
which about 30% of the oligonucleotide is labeled.
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Figure 3.11 HPLC analysis of labeling efficiency of native DNA (5’-dGCGTAATACGACTCACTATAG-3’) and
Se-DNA (5’-dSeTGCGTAATACGACTCACTATAG-3’). Blue: result after native DNA react with dye; pink: result after Se-DNA react with dye; A): monitored under 260 nm; B) monitored under 490 nm. It shows
about 34% of the 5’-Se-T containing oligonucleotides are labeled with fluorescent dye. Samples were
eluted with a linear gradient from buffer A (20 mM triethylammonium acetate, pH 7.1) to 60% buffer B
(50% acetonitrile, 20 mM triethylammonium acetate, pH 7.1) in 20 min.

The fluorescent-labeled DNA was analyzed by MS, UV and HPLC. Results were shown in Figure
3.12, 3.13 and 3.14. The fluorescent dye was also analyzed by HPLC. Figure 3.15 is the HPLC profiles of
dye 5-IAF, dye-labeled DNA and their co-injection. The dye compound and dye-labeled DNA had different retention time.
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Figure 3.12 MS spectrum of 5’-fluorescein-labeled DNA-22mer.
C237H284N83O134P21Se; [M]+: 7173 (calc. 7169); [M]2+: 3588 (calc. 3585).

Its

molecular

formular:

Figure 3.13 HPLC analysis of fluorescent dye-labeled DNA-22mer (5’-mT-GCGTAATACGACTCACTATAG-3’).
This analysis was performed on a Zorbax SB-C18 column (4.6 x 250 mm) with a linear gradient from
Buffer A (20 mM triethylammonium acetate, pH 7.1) to 60% Buffer B (50% acetonitrile, 20 mM
triethylammonium acetate, pH 7.1) in 20 min. Profile A was monitored under 260 nm, and Profile B was
monitored under 490 nm. Retention time: 16.0 min.

Figure 3.14 UV analysis of the dye-labeled DNA-22mer.
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Figure 3.15 HPLC analysis of fluorescein compound 5-IAF, dye-labeled DNA, and their co-injection. Blue:
dye compound 5-IAF; pink: labeled DNA; red: co-injection. A): monitored under 260 nm; B): monitored
under 490 nm. Sample was eluted with a linear gradient from buffer A (20 mM triethylammonium acetate, pH 7.1) to 60% buffer B (50% acetonitrile, 20 mM triethylammonium acetate, pH 7.1) in 20 min.

Under the same reaction condition, the corresponding non-modified native DNA did not react
with the labeling reagent. This indicated that the activated dye specifically reacted with the selenol
(DNA-SeH), without reacting with other nucleophiles in DNA (such as the amino and phosphate groups).
Analyzed by HPLC (Figure 3.11), efficiency of the dye incorporation into the Se-DNA is satisfactory (34%
yield), comparing with literature on the fluorescent labeling (20-40% yield)155,156. During the labeling, the
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DNA dimer with a diselenide bond was observed as the main by-product, whose retention time was 12.3
min. The product peak had absorbance under both 260 nm and 490 nm, and the retention time was 16.0
min. The dye-labeled DNA has color of the dye (yellow) and can be purified by reversed-phase HPLC or
gel electrophoresis. As expected for its UV-visible spectrum (Figure 3.14), this dye- labeled DNA absorbs
at both 260 and 490 nm, contributed by the DNA nucleobases (260 nm) and fluorescein (490 nm). In addition, their intensity ratio is approximately 3:1, which is consistent with the calculation. Analysis with
MALDI-TOF mass spectrometry also confirmed the integrity of the dye-containing Se-DNA (Figure 3.12).
To demonstrate the usefulness of our novel strategy for DNA labeling, we performed a DNA
polymerization reaction by using the fluorescein-labeled DNA as a primer. The time-course primer extension reaction was performed using this synthetic fluorescent DNA primer (P) 5’-dmTGCGTAATA
CGACTCACTATAG-3’ (mT is 5’-modified thymidine) and template (T), 3’-dCGCATTATGCTGA GTGTATCCGT
TGGA CTACTCCGGCTTTCCGGCTTTGCATGT-5’157,158. Due to the fluorescent group at 5’ terminal of primer,
usage of radioactive 32P was avoided. In a buffer of 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2 and 0.5 mM
DTT, DNA polymerization reaction (48 μL scale for one reaction) was performed using equimolar ratios
(6 μM, final concentration) of the primer and template, equal concentrations (0.1 mM each, final concentration) of natural dNTPs and Klenow (exo-, 0.02 U/μL, final concentration) After adding Klenow enzyme into these tubes, the reaction was initiated. Aliquots (6 μL each) were taken at the 0.1 min (t = 0.1)
and the other time points (0.5, 1, 2, 4, 10, 30, 60 min). To quench the reactions, the aliquots were added
into the individual tubes containing the gel loading dye solution (6 μL, containing 100 mM EDTA, sat.
urea, 0.05% bromophenol blue, 0.05% xylene cyanol). dTTP or the polymerase was absent from the negative control reactions. The samples were analyzed by 15% denature PAGE-gel. After the gel electrophoresis, the gel was placed in the Ultra-Lum Omega molecular imaging systems and excited by blue light
(450-490 nm). Because of the dye labeling, the DNA polymerization reactions became visible (Figure
3.16A). A time-course experiment of the polymerization reaction can be directly visualized, while the
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corresponding experiment using the non-labeled DNA was not visible under blue light or UV (Figure
3.16B). The polymerization reaction by non-fluorescent DNA primer was also performed using the identical reaction conditions. After the gel electrophoresis, the gel was placed on plastic wrap over a UV fluorescent TLC plate. In a dark room, shine a hand-held UV light source (254 nm; short-wavelength) on the
surface of the gel, and the dye in the TLC plate was excited to show green color. If the DNA quantity was
high enough to be visualized, some dark areas should be observed where DNA in the gel absorbed the
UV light. Yet, our experiment indicated that the polymerization reaction was not visible under our experimental condition. This experiment indicated that the DNA polymerase efficiently recognized the dyemodified DNA, since the label was purposely incorporated to the 5’-terminal in order to avoid the potential interference with DNA polymerase. Moreover, the sensitivity of this non-radioactive labeling can
reach up to the level of 30 pmol. The full-length product with the labeled dye was also confirmed by MS
analysis (Figure 3.18). Our experimental results demonstrate that the dye-labeled Se-DNA is an efficient
primer for DNA polymerase, and the reaction efficiency is almost identical as non-labeled DNA.
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Figure 3.16 DNA polymerization reaction monitored with the fluorescent dye-labeled DNA-22mer. A)
The gel was shined with blue light (450-490 nm). B) The gel was attempted to visualize by the UV shadowing.

Figure 3.17 MS spectrum of full-length product of DNA polymerization reaction. Dye-DNA Sequence (5’dmTGCGTAATACGACTCACTATAGGCAACCTGATGAGGCCGAAAGGCCGAAACGTACA-3’)
Its
molecular
formular: C568H695N226O329P55Se; [M]+: 17730 (calc. 17734).
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In summary, we have successfully synthesized the 5’-Se-thymidine and the corresponding
phosphoramidite and incorporated it into oligonucleotides. Using the 5’-Se-moiety for the post-synthetic
modification, DNA can be simultaneously labeled under a mild condition during the deprotection step.
Furthermore, we observed that the non- isotope labeled DNA is well recognized by DNA polymerase,
and DNA polymerization can be easily visualized because of the dye labeling. We have demonstrated the
proof of principle of this convenient strategy for the post-synthetic modification. Our facile and novel
labeling strategy is useful in DNA and RNA probe preparation for convenient visualization and monitoring of bio-reactions, like DNA replication, transcription and mRNA translation. This strategy also offers a
new tool for nucleic acid detection.
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3.4 Synthesis of 5-Selenium-Cytidine DNA for Structural and Enzymatic Study
The synthesized Se-DNAs are stable in synthesis and deprotection. The Se-oligonucleotides were
purified with DMTr-on and then DMTr-off. The purification programs were the same as discussed above.
The typical HPLC profiles of the synthesized SeC-oligonucleotide are shown in Figure 3.19. According to
the HPLC analysis of the crude Se-DNA (5’-DMTr-T-SeC-T-3’), the coupling yield of SeC-phosphoramidite
was over 95%. All SeC-DNAs were characterized and analyzed by MS and HPLC (Table 3.9).

Figure 3.18 Reversed-phase HPLC analysis of crude DMTr-on Se-DNA (5’-DMTr-TC5SeT-3’) after cleavage
from the solid support and deprotection. The HPLC analysis was performed on a Zorbax SB-C18 column
(4.6 x 250 mm) with a linear gradient from buffer A (20 mM triethylammonium acetate, pH 7.1) to 70%
buffer B (50% acetonitrile, 20 mM triethylammonium acetate, pH 7.1) in 20 min; the Se-DNA retention
time was 20.3 min.
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Table 3.9 MALDI-TOF MS Data of the 5-Se-C DNAs.
entry
1

Se-oligonucleotide
2’-Se
Se
5’-GdU GTA- C-AC-3’
C79H101N30O46P7Se2
Se

2

5’-ATGGTG- C-TC-3’
C89H114N32O54P8Se

3

5’-CTCC- C-ATCC-3’
C85H113N27O53P8Se

4

5’-CTT- C-TTGTCCG-3’
C107H140N32O69P10Se

Se

Se

measured (calcd.) m/z
+
[M] : 2581.6 (2581.5)
+ +

[M+H ] : 2823.7
(2823.8)
+ +

[M+H ] : 2688.6
(2688.7)
+ +

[M+H ] : 3368.3
(3368.6)

We also carried out UV-melting experiment to study thermostability of the SeC-DNAs, comparing
with the corresponding native ones. The melting temperatures are listed in Table 3.10. Our experimental results indicate that the SeC-DNA duplexes are as stable as the corresponding natives and the Sefunctionality at 5-position of cytidine causes no significant perturbation.
Table 3.10 UV Melting Temperatures of the SeC-DNAs.
entry

Se-oligonucleotide pairs

melting temp
o
( C)
40.3 ± 1.0

1

5’-ATGGTGCTC-3’
5’-GAGCACCAT-3’

2

5’-ATGGTG- C-TC-3’
5’-GAGCACCAT-3’

40.3 ± 1.0

3

5’-CTCCCATCC-3’
5’-GGATGGGAG-3’

36.5 ± 1.0

4

5’-CTCC- C-ATCC-3’
5’-GGATGGGAG-3’

Se

36.3 ± 1.0

5

5’-CTTCTTGTCCG-3’
5’-CGGACAAGAAG-3’

44.9 ± 1.0

6

5’-CTT- C-TTGTCCG-3’
5’-CGGACAAGAAG-3’

43.6 ± 1.0

7

5’-GTGTACAC-3’
(self-complementary)

27.5 ± 1.0

8

5’-G-dU2’-Se-GTA- C-AC3’ (self-complementary)

Se

Se

Se

27.8 ± 1.0
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To further understand the Se-modification, we also carried out the structural study of the selfcomplementary SeC-DNA (Figure 3.19). Although the reason was still unclear, the crystallization of the
Se

C-DNA was facilitated by the incorporation of 2’-Me-Se-dU into the oligonucleotide. With the assis-

tance of the 2’-Se-functionality, the Se-DNA crystallized within two weeks. Se-DNA crystals were observed in 20 out of 24 diversified buffer conditions (Nucleic Acid Mini Screen kit, Hampton Research). In
contrast, the corresponding native DNA did not crystallize in these buffer conditions over two months.
Later, the Se-DNA crystal structure was determined at 1.80 Å resolution. The superimposition of this SeDNA structure and corresponding native one is shown in Figure 3.19 and reveals that these two structures are virturally identical. The structural characterization result is consistent with our thermostability
study. The data were processed using HKL2000 and SHELXS. Data collection, phasing, and refinement
statistics of the determined Se-DNA structure (3IJN) are listed in Table 3.11 and 3.12.

Table 3.11 Data collection and Statistics.
Wavelength, Å
Resolution range, Å
(last shell)
Unique reflections
Completeness, %
Rmerge ,%
<I/ (I)>
Redundancy

0.9795
30.0-1.8
(1.86-1.80)
2263 (134)
97.8 (85.0)
7 (44.5)
38.2 (2.9)
15.6 (4.6)
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Table 3.12 Structure Refinement and Model Statistics.
Structure (PDB ID)
Space Group
Cell dimensions: a, b, c (Å)
Resolution range, Å
(last shell)
Rwork , %
Rfree , %
Number of reflections
Number of atoms
Nucleic Acid
Heavy Atoms and Ion
Water
R.M.S. deviations
Bond length, Å
Bond angle,
2
Average B-factors, Å
All atoms
Wilson plot
Overall anisotropic B-values
B11/B22/B33/

5-Se-C-DNA (3IJN)
P4(3)2(1)2
42.581,42.581,24.548
30.00 - 1.80
(1.86 - 1.80)
20.6 (35.2)
23.4 (36.0)
2263
164
2 Se
34
0.009
2.042
12.12
null
0.76/0.76/-1.51

We also observed that the SeC and G form a base pair similar to the native C:G pair (Figure 3.19 B
and C), and its hydrogen bond lengths are 2.8, 2.8 and 2.7 Å. In addition, the furanoses displayed the 3’endo sugar pucker, and the 5-Se atom pointed to the major groove of the duplex. Moreover, the weak
5-CH3/π interaction between the thymine and its neighboring base was disrupted by the selenium insertion. However, the 5-Se-atom on the cytosine allows better electron delocalization and may contribute
to the stacking interaction, thereby compensating the duplex distablization by the 5-CH3/π disruption.
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Figure 3.19 SeC-DNA crystal structures (Se in gold). (A) Superimposed structures of the native DNA
(GTGTACAC in gray; PDB ID: 1DNS) and the SeC-DNA (G-dU2’-Se-GTA-SeC-AC in green; PDB ID: 3IJN). (B) The
structure model and the electron density map of SeC:G base pair. (C) Superimposed structures of native
C:G and SeC:G base pairs in gray and green, respectively.

We did the DNA methyltransferase reaction to test different cytosine modifications’ effects on
methylation reaction. Figure 3.20 shows the MALDI-TOF MS results of different oligonucleotides after
methylation. In the mass spectra, multiple peaks showed up for one target oligonucleotide molecules,
and the mass difference is from the DNA isotopic distribution. When one DNA sequence is modified, either with selenium or with methyl group, the efficiency of methyl addition on the complementary strand
will be altered. In Figure 3.20, spectra A, B and C show the methylation effects on oligo A, when oligo B
was modified differently. When oligo B was native, about 36% of oligo A was methylated (Figure 3.20A,
peak 3910 to 3924). But when the oligo Bse and oligo Bme were applied, the percentage of methylation
on oligo A was changed to 52% and 100% respectively (Figure 3.20B and C). Similarly, spectra D, E and F
show the methylation effects on oligo B when oligo A was modified differently. About 37% of oligo B
would be methylated under native duplex conditions (Figure 3.20D, peak 3990 to 4004). And when the
oligo Ase and oligo Ame were applied, the percentage of methylation on oligo B was changed to 68%
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and 95% (Figure 3.20E and F). Our results indicated that our modifications on one oligonucleotide would
cause the facilitation of methyl addition in its complementary strand. And relatively, selenium modification on 5-position of cytosine at active site can enhance more than methyl group.

Figure 3.20 Selenium modification effects on DNA methyltransferase interaction. A: oligo A; B: oligo Ase;
C: oligo Ame; D: oligo B; E: oligo Bse; F: oligo Bme.

Consequently, we carried on experiments to test the results that 5-position modification, including selenium and methyl group, generated on the endonuclease Hinp1I’s hydrolysis. As talked about
above, the duplex DNA samples were digested under standard manufacturer conditions. Figure 3.21
shows different results of endonuclease’s digestion under different modifications. To completely understand the reaction progress and different impacts of modifications, we chose to monitor the oligo A and
oligo B separately. In Figure 3.21A, B and C, native oligo A was radioactive labeled and monitored. When
the complementary sequence is native oligo B, about 95% of oligo A was digested after reaction overnight. But when the complementary was oligo Bme and oligo Bse, the cleavage percentage would drop
to 60% and 10% respectively. Obviously the 5-position modification on the complementary strand could
cause inhibition to the digestion of oligo A. In Figure 3.21D, E and F, oligo Ame was radioactive labeled
and monitored. Here we can see no matter the complementary strands were native or modified (Se or
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methyl), the digestion percentage was only less than 10%. This indicates that the endonuclease Hinp1I
might not be able to recognize and cleave methylated oligonucleotides. Similar conclusion can be drawn
from Figure 3.21G, H and I. The selenium modification on oligo Ase could result in more inhibition than
oligo Ame. We also radiolabeled and monitored oligo B in the same reaction conditions. Figure 3.22J, K
and L indicate that, the digestion intensity would be different if the complementary sequence was differently modified (100%, 80% and 7%). And to our surprise, oligo B seemed to be digested much faster
that oligo A. This phenomenon probably indicates the endonuclease has unequal preference to the two
complementary strands. Also the oligo Bme and oligo Bse were radiolabeled and monitored, and similar
resultes were observed (Figure 3.21M, N, O, P, Q, R). The oligo Bme was barely hydrolyzed (less than
10%) no matter how the complementary sequences were modified (M, N and O). The oligo Bse’s digestion was completely inhibited, which suggest that selenium modification had extremely strong inhibition
to the endonuclease.
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Figure 3.21 Endonuclease Hinp1I’s digestion to oligonucleotides with different modifications.
In summary, we have successfully synthesized the novel SeC-phosphoramidite and incorporated
it into DNAs for biophysical and structural studies. Our experimental results indicate that the Sefunctionality at the 5-position of cytidine causes no perturbation on the DNA duplex structure, and the
Se-DNA duplexes are as stable as the corresponding natives. The Se-DNA crystal structure is virtually
identical to the native one, and the SeC:G base pair is well preserved as the native C:G pair. This synthetic
and biophysical research on 5-methylcytosine with the selenium modification encourages further investigation on m5C, methyltransferase inhibitor design, and its epigenetic mechanism. Furthermore, the 5methyl-Se-cytosine (SeC) offers a useful derivatization strategy for nucleic acid X-ray crystallography. In
addition, the 5-position modification can cause some interesting effects on DNA methyltransferase and
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endonuclease. Basically, derivatizations on 5-position will greatly facilitate the methyl groups addition;
meanwhile the selenium modification has more obvious impact than methyl group modification. On the
other hand, 5-position modification is able to inhibit endonuclease digestion. Selenium modification
could completely inhibit the cleavage, no matter the modification is on the active site or the complementary strand. Methyl group modification had impact as well; but compared with selenium, the inhibition influence is weaker. These interesting results are probably due to the different enzyme structure
and functions, which need further work to explore.
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3.5 Synthesis of 4,5-Diselenium-Thymidine Nucleoside and DNA
All the DNA oligonucleotides were chemically synthesized in a 1.0 μmol scale using an ABI392 or
ABI3400 DNA/RNA Synthesizer. The ultra-mild nucleoside phosphoramidite reagents were used in this
work (Glen Research). The concentration of the 2-Se-T phosphoramidite was identical to that of the
conventional ones (0.1 M in acetonitrile). Coupling was carried out using a 5-(benzylmercapto)-1Htetrazole (5-BMT) solution (0.25 M) in acetonitrile. The coupling time was 25 seconds for both native
and modified samples. 3% trichloroacetic acid in methylene chloride was used for the 5’-detritylation.
Synthesis were performed on control pore glass (CPG-500) immobilized with the appropriate nucleoside
through a succinate linker. All the oligonucleotides were prepared with DMTr-on form. After synthesis,
the DNA oligonucleotides were cleaved from the solid support and fully deprotected by the treatment of
0.05 M K2CO3 solution in methanol for 8 hr at room temperature. The 5’-DMTr deprotection was performed in a 3% trichloroacetic acid solution for 2 min, followed by neutralization to pH 7.0 with a freshly
made aqueous solution of triethylamine (1.1 M) and extraction by petroleum ether to remove DMTr-OH.
The DNA oligonucleotides were analyzed and purified by reversed-phase high performance liquid chromatography (RP-HPLC) both DMTr-on and DMTr-off, following the same procedure we used in
previous work. The MS results are shown in Table 3.13.

Table 3.13 MS values of the 4,5-Se-T-containing DNAs.
Entry

Oligonucleotide

Molecular Formula

Isotopic Mass

Measured (calc.) m/z

1

5'-CTCCCA TCC-3'

C84H103N27O52P8Se

2736.1

[M+H ] : 2738.6 (2737.1)

2

5'-ATGG TGCTC-3'

Se

C88H104N32O53P8Se

2872.1

[M+H ] : 2873.6 (2873.1)

3

5'-CTTCT TGTCCG-3'

C106H128N32O68P10Se

3417.1

[M] : 3417.9 (3417.1)

4

5’-GdU2’SeMeG TACAC-3’

C78H99N30O45P7Se2

2631.1

[M] : 2631.1 (2631.1)

Se

Se

Se

+ +

+ +

+

-
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We also performed pH adjustment to study how this double selenium modification will impact
the thymidine UV absorbance and cause red shift. According to our previous work, the selenium functionality in nucleobase is able to generate UV absorbance red shift. For example, the maximal absorbance wavelength for 5-Se-T is 305 nm, and for 4-Se-T is 360 nm. We assume that by introducing two selenium atoms in one nucleobase, the maximal absorbance wavelength can shift further to the long wavelength area, and generate some stronger color to the nucleic acids.
We used the synthetic double selenium containing nucleoside to do the experiment. After dissolving the compound a in methanol solution, our UV spectrum shows the compound had absorbance at
305 nm, which is because of the 5-Se-functionality. After adding 50 mM K2CO3/MeOH solution, the
deprotection reaction happened. In the basic condition, the NH at 3-position was deprotonated to generate compound c, which had absorbance at 360 nm. The deprotection reaction was complete in about 3
hours, and the 305 nm peak completely disappeared. However, the basic condition could cause the decomposition of compound c, especially in long time. Our UV results indicated that after staying in the
K2CO3 environment for over one day, the compound c was decomposed, and UV peak at 360 nm would
disappear. We suspected that it was due to the substitution reaction at 4-position that could replace the
selenium with methoxy group.
Furthermore, after adjusting the solution to neutral, the spectrum red shift was observed. Under
neutral condition, the 3-position would be protonated, and the selenol group was formed at 4-position.
This compound b generated an absorbance at 390 nm, and it could stay stable for several days. This phenomenon indicated that the double selenium modification was able to generate absorbance at higher
wavelength area, and it is possible to provide nucleic acids with detectable color change. The possible
reaction and UV-vis spectrum were shown in Figure 3.22 and Figure 3.23.
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Figure 3.22 Structure change of 4,5-Se-T nucleoside under basic pH condition.

Figure 3.23 UV-visible spectrum of 4,5-Se-thymidine under pH change.
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3.6 Facilitation of Selenium Modification on Nucleic Acid Crystallization
We observed that, the DNA with selenium modification could crystallize in several weeks when
using the Hampton Research nucleic acid mini-kit. After screening, 22 out of 24 buffer conditions gave us
nice crystals within three weeks. However, the native DNA failed to crystallize under the same conditions. The crystals we obtained included needle shape, stick shape and diamond shape. Among the
screen kits, buffer 7 and 8 generated the nicest crystals. Table 3.14 shows the comparison of Se-DNA
and native DNA’s crystallization process. Figure 3.24 shows some of the crystals of Se-DNA. Finally the
crystals from condition 8 was mounted and used for data collection. The structure was solved in high
resolution (1.3 Å). Figure 3.25 is the crystal structure of Se-DNA 8mer 5’-GTGT2seACAC-3’.

Table 3.14 Comparison of DNA crystallization process. A: Se-DNA; B: native DNA.
A:
screen kit

1 (7, 13, 19)

2 (8, 14, 20)

3 (9, 15, 21)

4 (10, 16, 22)

5 (11, 17, 23)

6 (12, 18, 24)

crystallization
time/shape/size

3 weeks/
Needle/0.03mm

3 weeks/
Needle/0.03mm

3 weeks/
Needle/0.03mm

3 weeks/
Needle/0.03mm

X

3 weeks/
stick/0.06mm

3 days/
Stick/ 0.06mm

2 weeks/
diamond/0.06mm

X

3 weeks/
stick/0.06 mm

3 weeks/thick
stick/0.04 mm

3 weeks/thick
stick/0.04 mm

3 weeks/thick
stick/0.04 mm

3 weeks/thick
stick/0.04 mm

3 days/thick
stick/0.04 mm

3days/big needle/0.04 mm

3 days/thick
stick/0.06 mm

3 days/thick
stick/0.06 mm

3 weeks/
stick/0.06 mm

3 weeks/
stick/0.06 mm

3 days/thick
stick/0.06 mm

3 weeks/
stick/0.06 mm

3 weeks/
stick/0.06 mm

3 weeks/
stick/0.06 mm

screen kit

1 (7, 13, 19)

2 (8, 14, 20)

3 (9, 15, 21)

4 (10, 16, 22)

5 (11, 17, 23)

6 (12, 18, 24)

crystallization
time/shape/size

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

B:
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Figure 3.24 Se-DNA crystals using nucleic acid mini-kit condition.

Figure 3.25 Crystal structure of DNA 8mer 5’-GTGTseACAC-3’.
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4.

CONCLUSIONS
This strategy of the oxygen replacement with the other chalcogen elements, especially seleni-

um, opens novel research avenues of nucleic acids, including therapeutic discoveries, structure and
function studies, mechanism and catalysis investigations, and material and nano-science research. Since
selenium has the unique application in X-ray crystallography, the Se-nucleic acids have great potentials
in facilitating phasing and crystallization for 3D structure determination of nucleic acids, protein-nucleic
acid complexes, as well as small molecule-nucleic acid complexes. In addition to the regular duplexes of
DNAs and RNAs, nucleic acids can have highly diversified secondary and tertiary structures, such as
bulges, junctions, i-motifs, triplexes, and quadruplexes. The further advances in this field, including rationally designed interactions (e.g., major groove recognitions by small molecular ligands), rely on the
new structure determination. As we talked above, selenium modification has been generated in different positions of nucleic acids, generating different functions. The Se modification at 5-position of
thymdine could generate novel intramolecular interactions, and this derivatization at major groove may
interfere nuclease recognition and improve nucleic acid drug stability. Also, Se modification at 5’terminal position could be good labeling probe for nucleic acid detection and assay. In addition, the Se
modification at 2-exo position of thymidine could dramatically discriminate DNA wobble pair stability
and enhance the Watson-Crick base pair stability. Plus, the Se modification at nucleobase of cytidine
could retard cytidine methylatransferase interaction and help for novel methyltransfease inhibitor design. Furthermore, Se modification, either on sugar or on nucleobase, was able to facilitate the nucleic
acid crystallization process. Overall, we are confident that our novel Se-derivatization strategy will significantly facilitate the process of structure determination and revolutionize the structure-based drug design and discovery in order to conveniently target nucleic acids and protein-nucleic acid complexes with
diversified interaction modes and ligand structures. The results of the structural studies will provide di-
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rect guidance and useful platforms for further optimization of existing drugs and the discovery of novel
therapeutics with high specificity, potency and low toxicity.
Furthermore, selenium is an essential element to human health, and the Se-modified DNAs and
RNAs show strong resistance to nucleases and cause no significant structural perturbations. Thus, the
Se-nucleic acids may have tremendous potentials in therapeutic development and drug discovery as
well. In addition, since selenium can form strong Au-Se bond, selenium may be useful in gold nanoparticle derivatization and property tailoring. This atom-specific modification of nucleic acids with the
chalcogen elements opens many novel doors for fundamental studies of structures, functions and applications of nucleic acids. We are confident that this novel strategy also has great potentials in investigating structures, functions, and drug discovery of small molecular ligands complexed with nucleic acids.
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APPENDIX-NUCLEIC ACIDS MINI SCREEN KITS
Application and Features
Crystallization screen for nucleic acid fragments; Can be used to screen a matrix of pH, polyamine and ions; Uses MPD as the primary precipitant.
Description
The Nucleic Acid Mini Screen is an efficient screen formulated to assist in the determination of
preliminary crystallization conditions of nucleic acid fragments. The formulation is based upon the publication “A Highly Efficient 24 Condition Matrix for the Crystallization of Nucleic Acid Fragments” where
the preliminary crystallization conditions of 35 nucleic acids were determined utilizing this formulation.
Samples include DNA-Drug complexes, C-Tetrad and G-Quartet Motifs, RNA oligomers, and others. By
using 1 to 4 mM oligonucleotide stock concentration, the screen requires less than 100 μl of sample. The
screen is typically performed at 4°C although room temperature incubations can also be performed. To
evaluate the effect of equilibration kinetics as well as initial and final sample concentrations, the screens
are typically performed using the hanging or sitting drop vapor diffusion method with two drops on a
slide (1 μl + 2 μl and 2 μl + 2 μl), side by side. The 24 well format of the mini screen provides for a fast
setup and uses small amounts of sample. This makes it possible to cost-effectively screen many sequences as well as variations of a particular sequence. The composition of the Nucleic Acid Mini Screen
allows one to apply the formulation to other nucleic acids such as deoxy- and ribozymes, pseudoknots,
and tRNAs. Each Nucleic Acid Mini Screen kit contains 24 unique reagents, 1.0 milliliter each plus a 250
milliliter volume of dehydrant (35% v/v MPD). All solutions are formulated using ultra-pure water and
are sterile filtered. The detailed compositions are listed as table A1.
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Table A1 Nucleic acids mini screen kit conditions.
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